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ABSTRACT
One important objective of prostate cancer (PCa) research is to understand
the molecular basis underlying the progression of these cancers from an androgen
dependent to an androgen independent state. Hypermethylation of the promoter
CpG islands is associated with the transcriptional silencing of specific gene sets in
each tumor type and subtype. Transcriptional silencing of antitumor genes via
CpG island hypermethylation could be a mechanism mediating PCa progression
from an androgen-dependent to an androgen-independent state.
Hypermethylation associated gene silencing has been reported for a great
number of genes in PCa with the exception of the genes that Ilndergo methylation
associated silencing specifically during cancer development to androgen
independence. The first aim of this thesis is to identify novel glenes which undergo
DNA hypermethylation associated gene silencing during the cancer progression.
The androgen-dependent (AD , as defined as the inability of celill to proliferate in
the absence of androgen) PCa cell line LNCaP gives rise to the androgen-
independent (AI) subline LNCap generated by maintaining LNCaP in medium
with charcoal-stripped (CS) serum for over 30 passages. This lNCaP cell model
was used to identify differentially methylated sequences betwen the two
genomes using the Methylation-Sensitive Restriction Fingerprinting (MSRF)
technique. One sequence identified is located in a 5' CpG island, which
encompasses part of the promoter, exon 1 , and part of intron 1 , of the
Peroxisomal Membrane Protein 24 KD (PMP24) gene. PMP24 is silenced in
concert with the hypermethylation of its CpG island in AI LNCap and PC-3 cell
lines. The silencing is reactivated by the treatment with a DNA methyltransferase
inhibitor, 5-aza- deoxycytidine (5AZAdC). PMP24 is specifically silenced in PCa
cancer cell lines and shows potential antitumor properties. These results
demonstrate the utiity of MSRF in the identification of novel" d fferentially
methylated DNA sequences in the genome and suggest that hypermethylation-
mediated silencing of PMP24 is an epigenetic event involved in PCa progression
to androgen independence.
The next study investigated the molecular mechanism for DNA methylation
associated gene silencing of PMP24 in AI LNCap and PC-3 cell lines. We
demonstrated that PMP24 transcription is repressed by the disruption of
transcription factor binding to a critical cis-element by hypermethylation of its
promoter CpG island. We found a CpG containing activator protein 2 (AP-2) cis-
element in the intron 1 of PMP24 whose first CpG dinucleotidle is essential for the
sequence-specific protein binding and the promoter activity of the gene. We
presented first in eel/ufo evidence that the methylation of AP- cis-element alone
but not the whole CpG island , using a newly developed methylated
oligonucleotides treatment, is sufficient for the downregulation of PMP24. Our
study is the first to report that the silencing mechanism for PMP24 in AI LNCap
and PC-3 is mediated by the complete methylation of a single GpG site of AP-
cis-element in the intron 1 part of the CpG island , which interferes with
transcription factor binding. Most interestingly, the promoter CpG island of PMP24
is hypermethylated in AD LNCaP cells with the incomplete methylation specifically
at the AP- cis-element. The silencing of PMP24 in AD LNCaP cells was
reactivated not by the 5AZAdC treatment but by the treatment with Trichostatin A
(TSA), a histone deacetylase inhibitor. An alternative silencing mechanism for
PMP24 other than the interference with transcription factor binding by methylation
is therefore likely involved at this androgen-dependent stage.. During the androgen
ablation process, this mechanism is either evolved by the spread of methylation in
the promoter CpG island or selected against, leading to the methylation-dominant
silencing mechanism in the AI cells as seen in LNCap andl PC-3 cells.
Taken together, this thesis emphasized the important role of DNA
methylation in the progression of PCa into androgen independence. Particular
respect should be paid to the specific CpG dinucleotides in cis-elements critical for
the promoter activity, whose complete methylation could dominate the silencing
mechanism which is independent of androgen. This thesis also pointed to the
importance of monitoring the effects of cell culture on the methylation status of
genes. Most importantly, this thesis raised the possibility that the silencing
mechanisms for PMP24 could be different in AD LNCaP cells as compared to AI
LNCap and PC-3 cells. Either the evolution of such mechanism or the selectivity
against it during the androgen ablation process would result in a methylation-
dominant silencing mechanism of the genes such as PMP24 in AI cells and may
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1 CURRENT DISEADE MANAGEMENT OF PROSTATE CANCER
Prostate cancer (PCa) is a disease related to aging. Its incidence increase rate
with age is greater than that for any other cancer (Cook et at " 1969). This disease
is likely to become a more prominent and pressing public health issue as the
percentage of elderly men increases in the US. Indeed , PCa remains the most
common non-skin cancer and the second most common cause of cancer death
among American men (Jemal et aI. , 2002) Interestingly, most recent epidemiology
studies have started to show the trend of declined prostate cancer mortality rate
for younger age groups in both US and Canada (Labrie et aI. , 2004; McDavid et
aI. , 2004; Weinmann et aI. , 2004). Wide adoption of prostate-specific antigen (PSA)
test as prostate cancer screening for elderly men since it became available in
1986 in both countries may be accounted for this change yet the association
between them stil needs to be carefully studied and documented. One thing for
sure though is that it has changed the emphases of research and resulting health
care for PCa during the past two decades. With almost 20 year experience with
PSA test , an improvement in its specificity and accuracy is in need or additional
novel early detection markers need to be established. On the other hand , with
incr ?sed number of patients identified in the early stage of disease , traditional
treatments for prostate cancer such as surgery, radiation therapy, and hormone
manipulation have had success but at the same time showed limitations. One of
the big challenges in the current managements of the disease remains for a
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significant population of patients failed hormone therapy and become androgen-
independent.
PCa cells, like certain normal prostate epithelial cells , depend on a critical
level of androgenic stimulation for their continuous growth and survival. It is on this
basis that in the early 40' , Charles Brenton Huggins pioneered the use of
synthetic estrogen , diethylstilbestrol (DES) to block the pituitary-testicular axis
lower circulating levels of androgen , and in a consequence cause tumor
regression (Huggins and Hodges, 2002). Although DES fell out of favor due to its
serious adverse estrogenic effects on patients , the fundamental concept
supporting the androgen blockade for the PCa treatment remains essentially
correct and effective. In fact , a multitude of excellent means of ablating serum
androgens has become mainstay treatments for advanced PCa at present. These
include surgical orchiectomy and chronic treatment with luteiniiziing hormone-
releasing hormone (LHRH) analogs, alone and in combinatioll with nonsteroidal
antiandrogens such as flutamide (Eulexin), and bicalutamide Casodex), which
compete with androgen for androgen receptor binding and subsequent
conformational activation. Although these methods appear to be effective in
lowering circulating androgen and in turn causing cancer celllS death and tumor
regression , the initial favorable response of patients are just transient. It has been
estimated that about 20% of PCa patients wil suffer from reclllUent disease after
radical prostactamy. Essentially, all these patients wil have received hormone
therapy afterwards. Unfortunately, almost without exception , after the initial
responsiveness to the treatment, all the treated patients will develop androgen-
independent cancer and die of PCa within one or two years (Savarese et aI.
2001). Although androgen ablation therapy has been used to treat advanced PCa
=--= 
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for more than 60 years , cancer progression into resistance to tmatment remains
the hurdle of the field. There has been a lot of effort on the dinical side to
maneuver current available hormone therapy techniques such as (1) combined
androgen blockade versus monotherapy of LHRH (2) interm~ttent androgen
suppression versus continuous therapy (3) early androgen depnivation in the
course of disease versus delayed therapy. The challenges for the researchers is
to carefully dissect the molecular mechanisms of PCa progressuon and precisely
define the distinct patient populations such that more effective treatments can be
developed and selected for patients of different disease stage and different risk
factors for recurrence.
ANDROGEN INDEPENDENT PCA
1 Model Systems for PCa Progression
To study the molecular mechanism of PCa progression , experimental
models which resemble the biological characteristics of the disease are in need.
Almost all the current model systems for the study of PCa pmgmssion utilize
LNCaP cell line. LNCaP was established from supreclavicular lymph node
metastases in 1980 ((Horoszewicz et aI. , 1980). The cells express androgen
receptors (ARs) and adrogen-regulated gene such as PSA, PSMA. It is the first
established PCa cell line exhibiting androgen responsiveness.. The most
straightforward system is the long term in vitro culturing of LNCaP cells in the
hormone-deprived environment. Upon the initial switching to medium with
charcoal-stripped (CS) serum that is depleted of hormones including androgens,
the majority of the cells undergo apoptosis. Usually after 6-months of continuous
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cell culture in medium with CS serum , the remaining cells grow in an androgen-
independent manner (Figure 1). This progression mimics the clinical process of
the disease in the patients undergo androgen ablation therapy. Several androgen-
independent (AI , defined by the ability of this LNCaP subline to proliferate in the
absence of androgen) LNCaP sublines, including LNCaP 104-R1 and 104-
(Kokontis et aI. , 1998), AI LNCaP (Gao et aI. , 1999), LNCaP-abl (Culig et aI.
1999a), LNCaP-AI cells (Lu et aI. , 1999a), have been developed in different labs
using this experimental system. Although all these derivatives share similar
biological change , which is that the cells gain the ability to grow in the absence of
androgen , the molecular changes vary among these cells. For example , both
elevated AR mRNA level and downregulation of AR have been reported in AI
LNCaP cell lines (Freedland et aI. , 2003; Lu et aI. , 1999b; Zhoul et aI. , 2004a).
Moreover, Freedland et al. showed that clonal cancer lines can be established
from parental AI LNCaP cells and they exhibited differing gene expression and
differing in vivo biology. The heterogeneity of the LNCaP model system is
therefore evident and multiple pathways might be involved in progression of
LNCaP cells into androgen- independent growth.
To address the influence imposed by the microenvironment on the prostate
tumor cells during their progression into androgen-independence, animal models
have been established by either co- inoculation of LNCaP cells with prostate or
bone fibroblasts subcutaneously or orthotopical implantation of LNCaP cells in
castrated mice to give rise to AI LNCaP cells (Thalmann et aI. , 2000; Wu et aI.
"-o
1994; Zhou et aI. , 2004b). Nevertheless , all these models were developed from
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Figure 1. Experimental system resembling the PCa proglression 
in vitro.
Androgen-independent (AI , defined by the ability of this LNCaP subline to
proliferate in the absence of androgen) LNCaP cells (LNCap ) was established
by maintaining androgen-dependent LNCaP cells in medium wiith charcoal-
stripped serum(CS-FBS) for over 30 passages. Androgen dependence assay
showed that the parental LNCaP cells were unable to proliferate in the medium
with CS-FBS. LNCap cells became able to proliferate at the similar rate as
compared to parental LNCaP cells even in the absence of androgen.
CHAPTER I
"'"
2 Proposed Mechanisms for PCa Progressio
Androgens and their cognate nuclear receptors - androgen receptors (ARs)
are essential for the normal male sex differentiation and also believed to be a risk
factor in initiation and progression of PCa. With the accumulating number of
proteins identified to be associated with AR, it is now clear that AR exerts its
function as transcription factor through a large complex formed together with
additional nuclear proteins such as coregulators and general transcription factors
(Heinlein and Chang, 2002; Torchia et aI., 1998). In the absence of androgen
, AR
is bound to heat shock proteins (HSPs) 90, 70, 56 and 54 whiich stabilize the
tertiary structure and localize the inactive complex mainly in cytoplast (Veldscholte
et aI., 1992). Upon androgen binding to ligand binding domaiin (LBD) of AR, AR
undergoes immediate conformational changes with the dissociation from HSPs,
hyperphosphorylatio , dimerization and translocation into nllclear and hence
becomes an active transcription factor. As a transcription factor, AR can activate
or repress its target genes, so-called androgen regulated genes (ARGs) through
the binding to androgen response elements (AREs) in their promoter regions
(Eder et aI. , 2001; Prins, 2000).
As a critical player in both prostate gland normal development and
carcinogenesis, AR proteins are expressed in normal prostatiic 
epithelium as well
as primary prostate tumors. At one time, it was hypothesized that progression of
PCa into androgen-independence was associated with loss of AR expression as in
two h man androgen-independent PCa cell lines, PC-
3 and DU145, AR was
barely detectable or absent (Kaighn et aI., 1979; Stone et all.
, 1978). However
mtensive immunohistochemical studies of hormone-refractory patient specimens
failed this hypothesis. AR proteins are not only expressed in majority but also
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elevated in some of tumors with the development of androgen-independent PCa
(Edwards et aI. , 2003d; Latil et aI. , 2001a; Linja et aI., 2001c; Tmpman and
Cleutjens, 1997). In fact, it is now believed that the "AR signaling" remains intact in
most androgen-independent PCa cells in an environment low of androgens.
Several mechanisms have been proposed for the intact AR function in androgen-
independent PCa and will be further discussed in the next section. However, worth
mentioning is that down regulation and silencing of AR expression has also been
reported in some hormone-refractory cancers even not in majority (Edwards et aI.
2003c; Kinoshita et aI. , 2000c; Segawa et aI. , 2001), and both PC-3 and DU145
were after all established from patients with prostate cancer metastases.
1 AR Gene Alternations in PCa Progression
Most recently, a microarray-based gene profiling study has been performed
using seven pairs of isogenic hormone-sensitive and hormone-refractory human
prostate cancer xenografts. It revealed an unexpected result that the only
consistent change in all the seven pairs is a modest increase in AR mRNA (Chen
et aI. , 2004). The authors further demonstrated in vitro 
that the increased AR is
both required and suffcient for progression probably by converting antagonists to
agonists through a functional LBD. The elevated AR express~on and transactivity
can be attributed to several alternations of AR gene on the genetic level , including
gene amplification and point mutation as illustrated in Figure 2a, b (Feldman and
Feldmstn, 2001).
In several studies , the AR gene has been shown to be amplified in
approximately one-third of androgen-independent PCa, but in none of the samples
collected from the same patients prior to hormone therapy (Brown et aI. , 2002;
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Edwards et aI. , 2003b; Ford , III et aI. , 2003; Linja et aI. , 2001 bo). An increase on
AR mRNA level has been reported resulting from gene ampliffication (Latil et aI.
2001 b; Linja et aI., 2001a). A corresponding increase in AR protein expression
has also been found in paired androgen-dependent and androgen-resistant
tumors from same patients with AR amplification (Edwards et aI. , 2003a). However
it seemed that gene amplification is not the only mechanism responsible for the
increase of AR expression. In the same study, the authors also reported 35% of
cases without AR amplification showed elevated AR protein level , not significantly
different from the AR protein level in patients with AR amplificatiion. In these cases
without gene amplification , decrease in protein degradation or an increase in
protein stabilization may be the alternative mechanisms for increase in AR protein
level and the possibilities need to be further investigated.
Point mutations of AR gene do not increase AR protein directly but result in
promiscuous AR with broadened or changed ligand specificity (Figure 2b). AR
point mutations detected in numerous clinical samples can be found in a
comprehensive list in AR mutation database (ww.mcaill.ca/androaendb
(Gottlieb et aI., 1998). Interestingly, majority of the mutations are clustered in the
LBD of AR (Buchanan et aI. , 2001; Gelmann , 2002). These mlltated AR either
allow the binding, of the ligands which don t normally bind by loosening the binding
pocket relative to wide type AR , or allow the antiandrogen such as hydroxyflutmide
induces different conformational change compared to wide type ligated AR and
generate novel coactivator binding site to function as an AR agonist. All these
changes make AR a "super receptor" able to respond to a wide variety of ligands
at lower concentration. The cells bearing the AR mutations in turn gain cell growth
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Figure 2. Possible mechanisms for PCa progression 
into. androgen-
independence. a. Elevated AR proteins usually by gene amplifiication are
hypersensitive to low- level of androgen. b. Promiscuous AR res.ulted from gene
mutation has broadened or changed ligand specificity. c. AR can be activated in
an androgen-independent manner by growth factors or cytokunes throught various
signaling pathways including the mitogen-activated protein \kinase (MAPK) and
AKT (protein kinase B) pathways. d. In the bypass pathway, parallel survival
pathways , such as that involving the anti-apoptotic protein B-ceillymphoma 2
(BCL2), abviate the need for AR or its ligand. (modified from lFeldman and
Feldman , 2001)
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therapy and develop overall androgen independence. It has been revealed that
the AR mutation frequency is much higher in metastatic and androgen-
independent PCa as compared with primary tumors, 
sugges.ting! that AR mutation
is likely involved in progression rather than initiation of PCa. Although the true
incidence of AR mutation is not known, it has been estimatedl 
around 20-40%
(Taplin and Balk , 2004).
Although the increase in AR transactivation by either point mutation or gene
amplification has strong clinical association with the resistance to hormone
therapy, neither can be solely responsible for development of androgen
independence due to the low incidence rate. On the other hand, not all the
androgen resistant PCa showed increase of AR protein. In fact
, there are reports
of loss of AR protein expression with the development of hormone resistance
(Gnanapragasam et aI. , 2002; Kinoshita et aI., 2000b). Therefore, by whatever
mechanism, elevated AR protein level can at best be responsible for androgen
independence in a subgrouP of PCa cases.
2 AR Signaling Pathway Alternations in PCa Progression
For the larger population of patients with neither AR genetic alternations,
the mechanism by which AR retains its trans activity still need! to be determined.
Ligand-independent activation of AR by different substances reported in prostate
cancer cell lines is one favorable mechanism. In fact, several years of intensive
resea ch have demonstrated that cross-talk of AR with multiple intracellular
signaling cascades plays an important role in androgen independent PCa cell
growth.
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Activation of AR in the absence of androgen, so-called androgen-
independent AR activation, was first found in DU145 cells by peptide growth
factors such as insulin- like growth factor-1 (IGF-1), keratinocyte growth factor
(KGF), and epidermal growth factor (EGF), although some activation was not
associated with tumor cell proliferation (Craft et aI. , 1999b; Culig et aI. , 1994). The
cytokine interleukin-6 (IL-6) has also been shown to stimulate AR transactivation
and consequently AR-regulated gene expression in the absence of androgen in
LNCaP cells (Culig et aI. , 2002a; Hobisch et aI. , 1998c; Un et aI. , 2001a). Strong
clinical relevance has been provided by the observations of elevated IL-6 level in
both the sera of PCa patients and PCa specimens (Adler et all , 1999; Giri et aI.,
2001; Hobisch et aI. , 1998b; Shariat et aI. , 2001; Twille et at" 1995).
Although the exact mechanism(s) of these ligand- independent AR
activations is stil not fully understood , several evidences suggested that mitogen-
activated protein kinases (MAP kinases) may playa key role in androgen-
independent prostate tumor growth (Figure 2c). MAP kinases are serine/threonine
protein kinases, which can be activated by a cascade of intracellular signal
transduced upon the binding of growth factors such as EGF and IGF-1 to their cell
membrane receptors. Activated MAP kinases are able to subsequently
phosphorylate their target transcription factor proteins to modllllate gene
expression (Pearson et aI. , 2001). Among MAP kinase family, the most
extensively studied members are tracellular 
gulated inases (ERK1/2), c-Jun
terminal inases (JNK1/2/3) and the p38 family of kinases (Chatterjee , 2003).
By using pathway-specific inhibitors, it was demonstrated that IGF-1/EGF/KGF/IL-
6 activated AR through Ras/Raf/MEK/ERK pathway of MAP k~nase signaling
cascade (Craft et a\. , 1999a; Hobisch et a\. , 1998a; Yeh et a\., 1999b). In
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agreement with these results was the detection of activated ERK in a subset of
advanced PCa specimen by using phosphor-ERK specific antibody (Gioeli et aI.
1999). It has been shown that the activated ERK in turn induce AR transactivation
by phosphorylating specific site in N-terminal transactivation domain of AR (Culig
et aI., 1999b; Yeh et aI. , 1999a).
In addition to MAP kinase pathway, EGF and other growth factors can also
induce Pl3kinase/Akt (also known as PKB, protein kinase B) pathway (Figure 2c).
Akt is an oncogene involved in the regulation of cell survival. Akt, activated by a
cascade of upstream signaling induced by phosphatidylinositol 3-0H kinase
(PI3K), can suppress the apoptotic response and selectively enhance key growth
and survival factors by inactivating a number of proapoptotic proteins such as Bad
and Caspase-9 (Cardone et aI. , 1998; del Peso et aI. , 1997).. It has been reported
that AKT activation and activity are markedly increased in both xenograft (Graff
2002) and in vitro cell line model (Shi et aI. , 2004). These experimental results
strongly correlate to clinical observations. Phosphorylated (actilvated) form of Akt
is increased in poorly differentiated tumors compared to norma tissue, prostatic
intraepithelial neoplasia (PIN) or well-differentiated prostate cancer, although no
enhanced Akt expression has been found in human prostate tumor tissues (Ghosh
et aI. , 2003). Cross-talk between AR with Pl3kinase/Akt pathway has been
suggested in LNCaP cells in which activated Akt increased AR transactivity by
promoting degradation of GSK- , which in turn enabled the translocation of 
catenin to nucleus to function as an AR coactivator (Sharma et aI. , 2002).
AR is a phosphoprotein whose phosphorylation status is. closely correlated
to its transactivity as a transcription factor, it is not surprising tlhat any component
can induce and/or is involved in cell signaling pathway to modulate the
L..L
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phosphorylation state of AR is capable of transactivating AR. Besides the
pathways mentioned above , it has been demonstrated in LNCaP cells by
transfection assay that protein kinase A (PKA) and protein kinase C (PKC) can
increase AR transactivation (Culig et aI. , 2002b), probably through the interaction
with the N terminal transactivation domain of AR (Nazareth and Weigel , 1996;
Sadar , 1999). AR activation and PSA secretion can be induced independent of AR
in PCa cell lines by PKA activators such as forkolin and analogs of cyclic AMP,
which is the downstream second messenger of PKA signaling pathway
(Grossmann et aI. , 2001). Besides growth factors and cytokines , other
substances have been reported to be able to induce AR transactivity independent
of androgen range from metal like cadmium, thyroid hormone" to structural
proteins such as j3-catenin which is an adherens junction protein mediating cell
adhesion , and caveolin which is a component of caveolae membranes. They all
probably induce AR activity through one signaling pathway or the other. Although
there is no doubt that androgen independent AR activation is one very attractive
mechanism for PCa cells to gain growth advantage in the absence.of androgen
based on a large body of in vitro evidences , questions remain for which pathway is
particularly potent pathway involved in the progression , if or how these pathways
influence each other within cell. The clinical significance of this kind of AR
activation is even a bigger challenge.
Bypass of AR Signaling
In the last two sections , we discussed the alternations of AR during PCa
progression. These changes occur either on genetic level or cellular level by
different signaling pathways. Nevertheless , all of them lead to one same
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outcome - "gain of function" of AR in the absence of androgen which could give
cancer cells the same growth advantage as they have in the presence of
androgen. Therefore , they are really androgen- independent but AR-dependent. If
indeed one or a combination of these mechanisms could be responsible for the
progression of PCa cells with an expressed AR , none of them, unfortunately can
be used to explain the actual existence of hormone refractory patients with loss of
AR expression and hence loss of its function. Hence , hypotheses for androgen-
independent development of PCa with loss of AR function are as important as the
ones for gain of AR function. Because of the structural similarity shared by AR and
steroid hormone receptor, GR and PR , it is possible that AR function can be
replaced by GR and PR to regulation downstream target genes. Another
possibility is additional singling pathway for cell survival such as BCL2 pathway,
which is independent of AR (Figure 2d). The Akt signaling pathway can also be
constitutively induced by loss of a tumor suppressor gene , phosphatase and
tensin homolog deleted on chromosome 10 (PTEN), whose expression was found
absent in advanced PCa (Dreher et aI. , 2004; McMenamin et all. , 1999).
3 DNA METHYLATION IN PROSTATE CANCER
1 DNA Methylation and Cancer
1 DNA methylation in normal mammalian cells
The most frequent DNA methylation is addition of a methyl group to the
carbon/5 position of the cytosine ring, catalyzed by DNA methyltransferases
(DNMTs). The level and distribution patterns of DNA methylation in the genome
vary widely among different species (Bird , 2002). In mammalian cells , DNA
j.,
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methylation is restricted to cytosines that are located 5' to a guanosine in a CpG
dinucleotide. The resulting 5-methylcytosine (5 C) is unstable and can
spontaneously deaminate to give thymine. Over long periods of evolutionary time
this C-T transition leads to much lower presence of CpG dinucleotides in
mammalian genome. It also gives rise to one very important feature of mammalian
genome: short regions of 0. 2 kb in length normally devoid of methylation and
protected from high spontaneous mutation rate. These regions" which have higher
GC content and CpG dinucleotides at more frequency than the rest of genome
are named as CpG islands. Althought CpG islands can be located throughout the
genome including in gene exons, introns or even between genes, most of them
are found in the promoter region of genes. It was estimated that at least half of the
genes harbor promoter CpG islands. Hypermethylation of promoter CpG island is
associated with the transcriptional silencing of gene. In normall cells, promoter
CpG islands are mostly unmethylated except for the imprinted genes , transposons,
genes on inactivated X chromosome and genes silenced in specific tissue. Since
DNA methylation can affect expression of a gene without changes in DNA
sequences, it was termed as one kind of "epigenetic" changes as apposed to
genetic changes.
It is well recognized long ago that DNA methylation is reversible and rather
dynamic both temporally and spatially as ilustrated in Figure 3. During normal
mammalian development, the primordial germ cells of the embryo are not
methylated to any extent (Reik et aI. , 2001; Tada et aI. , 1997). After gonadal
differentiation and as the germ cells begin to develop, 
de novo methylation occurs
leading to substantial methylation of the DNA of mammalian sperm and egg cells.
Therefore, upon fertilzation , the genome of very early mammalian embryo is
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substantially methylated with differences inherited from paternal and maternal
alleles. The methylation level declines sharply to -30% of the typical somatic level
at the morula and early blastula stages in the preimplantation embryo (Kafri et a\.
1992). By the time of implantation , widespread de novo metlhylation by de novo
methyltransferase 3a and 3b (DNMT3a, 3b) re-establishes normal methylation
level and new patterns , depending on different cell lineages. The somatic cell
lineage is heavily methylated; trophoblast-derived lineages whiich give rise to the
placenta, yolk sac, etc. , are undermethylated; early primordial germ cells are
spared; their genomic DNA remains very mostly unmethylated until after
widespread de novo methylation occurs upon gonadal differentiation as described
above.
When somatic cells are further differentiated, the appearance and behavior
of the cells are largely determined by the genes expression pattern in the cells.
Since the association of DNA methylation and gene expressilOn was first described
for ribosomal genes in early 80's (Bird et aI. , 1981), a great nllmber of evidences
have showed that DNA methylation is involved in regulation of gene expression at
transcription level. Therefore , the pattern of 5-methlycytosine dilstribution in the
genome of differentiated somatic cells varies accordingly to dlefine the gene
expression pattern in different cell type. The methylation pattern, once established,
is inheritableln normal cell proliferation, the stable inheritance of existing pattern of
DNA methylation is ensured by maintenance methyltransferase, DNMT1 to
methYJate the newly synthesized daughter DNA strand using the parental strand









Figure 3. Changes in DNA methylation during mammalian cell normal
development and carcinogenesis. Very rapid changes in DNA methylation
during: (i) gametogenesis - de novo methylation by 
de novo methyltransferase 3a
and 3b (DNMT3a , 3b) gives rise to substantially methylated genomes in the sperm
and egg with differences in both the overall level of methylation and the pattern of
methylation in these genomes, and in (ii) the early embryo where a wave of
genome-wide demethylation occurs at the preimplantation s.tage (morula and early
blastula), and is succeeded shortly afterwards by large-scale 
de novo methylation
beginning at the pregastrulation stage. The pattern of somatic cells is largely
maintained by maintainance methyltransferase 1 (DMNT1). When the cell is
transformed into cancer cell, the pattern and level of methylation are disturbed by
regional de novo methylation and global demethylation. (modified from Human
Molecular Genetics 2 T. Strachan and A.P. Read)
JA.
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2 DNA methylation in cancer cells
C is a hotspot for genetic mutation as it can spontaneously deaminate to
become thymine. Methylated CpG dinucleotides are also more susceptible to UV-
induce mutation (Pfeifer, 2000) and G-T transversion by hydrocarbon carcinogen
(Yoon et aI., 2001). It has been reported that as great as 50% of point mutation in
coding region inactivating TP53 tumor-suppressor gene occur at 5 C (Rideout , III
et aI. , 1990). However, the more significant function of DNA methylation in
tumorigenesis is its involvement in the regulation of gene expression. The gene
expression profile is largely disturbed when the normal cells are transformed. So is
the pattern of methylation distribution in the genome. The early study of genome
wide comparison between normal and tumor cells showed that genome wide
hypo methylation is one of the featured DNA methylation changes in tumor cells
(Feinberg and Vogelstein , 1983; Feinberg et aI. , 1988). Some recent compelling
evidences suggested that hypomethylation is deeply involvedl in tumor initiation
and development by activation of transposons, inappropriate expression of
imprinted genes and distortion of centromeric DNA, leading to genomic instability
in general (EI Osta, 2004).
In contrast to genome wide hypomethylation in cancer cells, majority of the
regional CpG islands undergo hypermethylation as compared to normal cells. The
transcriptional silencing of genes, especially tumor-suppressor genes , is often
found t be associated with hypermethylation of their promoter CpG islands in
cancer cells. Interestingly, the abnormal promoter CpG island hypermethylation is
at least as common as genetic mutation in human cancers. Nearly 50% of the
genes whose germ line mutations cause familiar tumors are later found to be
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silenced associated with hypermethylation in sporadic forms. of cancers (Jones
and Baylin , 2002d). One great example is breast cancer 1, early onset gene
(BRCA 1) in breast cancer. BRCA 1 was first identified as gene whose germ line
mutation causes familiar breast cancer account for 10% of total incidence.
Recently, it was reported that in 10-15% of sporadic breast cancer, this gene
function was as well disrupted by methylation associated transcriptional silencing
(Esteller et aI. , 2000b). Moreover, the resulting overall gene-expression profiling is
similar as in breast cancer caused by BRCA1 germ line mutatiion (Hedenfalk et aI.
2001; van de Vijver et aI. , 2002). With the increasing number of genes identified to
undergo CpG island hypermethylation associated gene silencing in virtually all
types of cancers, it is now recognized that each tumor type as well as subtype has
a specific set of genes targeted for hypermethylation during carcinogenesis
(Costello et aI. , 2000; Esteller et aI. , 2001; Toyota et aI. , 1999b)
The significance of methylation-associated gene silencing in tumorigenesis
can be more appreciated with the re-examination of the KnUidson
s two hit model.
The model , which is stil fundamentally true in all human cancers, hypothesized
that the complete loss of function for a tumor suppressor gene requires
inactivation of both alleles of the gene. In addition to inactivatiing point mutation
and loss of heterozygosity (LOH), promoter CpG island hypermethylation
associated gene silencing now provides a third mechanism for the disruption of
gene function. Such inactivation of gene expression has been reported for a
growing Ii;?t of the genes known to be involved in tumorigenesis including
retinoblastoma 1 (RB1) in retinoblastoma (Ohtani-Fujita et aI., 1997), van Hippel
Lindau (VHL) in VHL disease (Herman et aI. , 1994; Prowse et aI. , 1997), DNA
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mismatch repair protein Mlh1 (MLH1) in microsatellte-unstable colorectal tumors
(Herman et aI. , 1998) and E-cadherin (CDH1) in gastric caner (Grady et aI. , 2000).
Unlike genetic changes , DNA methylation is reversible. This feature has
made DNA methylation a very attractive prevention and therapy targets for cancer
(Baylin, 2004; Egger et aI. , 2004b). It was hoped by reversing the abnormal DNA
methylation pattern in cancer, aberrant gene silencing mediated by epigenetic
events associated with transcriptional repression can be reversed consequently. In
fact , 5-aza- deoxycytidine (5AZAdC , decitabine), a demethylating agent, has
showed significant activity in several clinical trials for the treatment of
hematopoietic malignancies (Issa et aI. , 2004b; Ravandi et aI. , 2001 a). However
clinical Phase I and II studies with solid tumours have not been very promising
(Momparler et aI. , 1997b; Thibault et aI. , 1998a). Initial results revealed significant
cytotoxic side effect, demanding more stable and less toxic drugs , for example
zebularine (Cheng et aI. , 2003; Cheng et aI. , 2004).
2. Promoter CpG Island Methylation and Gene Silencing
1 Mechanism of promoter CpG island methylation associated gene
silencing
Located mostly in promoter region of the genes , the l1ypermethylation of
CpG ?lands is thought to repress gene transcription by interferiing with the
transcription initiation. Since methyl group can protrude into tile major groove of
the double helix required for binding of some transcription factor, one mechanism
can be easily envisaged for DNA methylation to suppress transcription is the direct
,:T:
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interference of methyl group in transcription factor binding to its target sequence
often with a CpG dinculeotide. Reduced binding affnity has been reported for
several sequence-specific transcription factors such as Sp1 (Clark et aI., 1997b)
and c-Myc (Prendergast and Ziff, 1991). On the other hand , methylated DNA
attracts a new group of protein binding to them with high affinity. One
characteristic of these proteins is they all contain the methyl-CpG binding domain
(MBD) which binds specifically to methylated DNA. Among them , MeCP1 and
MeCP2 are the first to be identified. MBD1 , MBD2 , MBD3 and MBD4 were later
identified based on the conserved MBD. Whether there is any DNA sequence
binding specificity for each one of these protein stil needs to be carefully
determined and defined.
In the past few years , our understanding DNA methylation associated
transcriptional repression has dramatically improved with the recognition of
connection between DNA methylation and chromatin structure. In eukaryotic
nucleus, DNA is packed into nucleosomes by histone proteins (Kornberg, 1974).
Histone proteins ' modifications like acetylation facilitate the formation of higher
order chromatin structure. Condensed chromatin is formed with histones which are
deaceylated through histone deacetylases (HDACs), on the transcriptional inactive
DNA (Hassig and Schreiber, 1997). In 1998, the association between MeCP2 and
HDAC activity was reported by two independent studies (Jones et aI. , 1998; Nan
et aI. , 1998). MBD1 and MBD2 were later found to be associated with
corepressors, such as Sin3 , which binds HDACs directly (Ng et aI. , 1999; Wade
and Wolffe , 1999). It is now believed that hypermethylated DNA forms condensed
chromatin structure to stay transcriptional inactive through the recruitment of
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HDACs onto DNA by methyl-CpG binding proteins such as MeCPs and MDBs
(Ballestar and Esteller, 2002; Jones and Baylin , 2002a).
2 Initiation of methylation associated gene silencing
Hypermethylated promoter CpG island is commonly convicted as a cause
in gene silencing. Not until recently, the relation between these two events was
challenged by several novel observations (Clark and Melki , 2002; Song et aI.,
2002b). Song et al showed in their elegantly designed experiment that
hypermethylation of GSTP1 CpG island in PCa cell lines such as LNCaP and
DU145 is initiated by a combination of transcriptional silencing and seeds of
methylation and achieved by following methylation spread. One of the other
supporting evidences is the study on the silencing of a retrovirallong terminal
repeat (L TR) fused to a GFP reporter gene in mouse leukemiia cells (Lorincz et aI.
2000). In this study, the initial silencing of GFP constructs was reactivated by
treatment with TSA alone. With the passaging of the transfected cells , the
silencing became resistant to TSA treatment but can be reactivated by 5AZdC,
suggesting hypermethylation of CpG island is rather a consequence to reinforce
the silencing than a cause. Together with several other similar observations in
various organisms such as mouse (Jahner and Jaenisch , 19'85) and plant (Arnaud
et aI. , 2000b) and human cell lines (Arnaud et aI. , 2000a; Song et aI. , 2002a;
Wong et aI. , 1999), a more plausible mechanism has been proposed (Figure 4)
(Turker, 2002) in which an initial transcriptional gene silencing and a feedback
loop between lack of transcriptional machinery binding and spread of DNA








Figure 4. Methylation associated gene silencing as a process. 
An expressed
allele (a) with a boundary between DNA methylation spreading and the open
chromatin region of the expressed promoter (Flag with ' ) undler- goes a dramatic
loss in transcription (Flag with ' ), which eliminates boundary 
aillowing methylation
to spread closer to promoter. A series of restoration and loss of promoter
expression (c - g) ensues, with transcription levels decreasing as methylation
encroaches. Finally, a sufficient density of methylation and/or methylation of
critical CpG sites (filled in red) occurs leading to stabilzation of "
permanent"
silencing (h , raised in black Flag). A by-product of this process is the formation of
variegated methylation patterns. (modified from Turker, 2002)
23.
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methylation. In agreement with all the evidences from the stud~es of 
in vitro
constructed DNA, a detailed study of CpG island methylation of estrogen receptor
13 (ER-I3) in different stage of PCa specimen by our lab provided first evidence for
methylation seeding and spreading in endogenous gene (Zhu et aI. , 2004a).
3. DNA Methylation Associated Gene Silencing in PCa
There is a large body of evidence for the involvement of DNA methylation in
PCa. The genes known to be silenced associated with hypermethylation of their
promoter CpG island have been nicely reviewed in a recent paper (Figure 5) (Li et
aI. , 2004). Tumor-specific target genes for methylation associiated silencing have
also been found in PCa (Singal et aI. , 2004). For example, methylation of the
glutathione $-transferase P1 (GSTP1) gene promoter, which occurs in the majority
of prostate cancers, is now known as a very early event specifiic for prostatic
carcinogenesis (Kang et aI. , 2004; Nakayama et aI. , 2004). In regard to androgen-
independent PCa, our knowledge of specific gene silencing associated with DNA
methylation is extremely limited. Indeed , AR is probably the only gene known
whose methylation in androgen independent PCa is more prevalent than in
primary PCa (Kinoshita et aI. , 2000a; Nakayama et aI. , 2000b). Identification of
more genes , that "Undergo methylation associated silencing specifically in this
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Figure 5. Epigenetic contribution to prostate cancer initiation , progression
and metastasis. There are various genes undergo DNA methylation-associated
gene silencing during development and progression of human PCa. (modified
from Li et aI., 2004)
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3.4 Conclusion
DNA methylation has to retain certain level and pattern to exert its effect on
normal gene expression in normal cells. Both the level and pattern of DNA
methylation are widely disturbed in cancer cells. Transcriptional silencing
associated with promoter CpG island hypermethylation is of particular interest
because it occurs in virtually all types of cancers and appears to target a set of
genes specific for tumor type and subtype. The current goals. of DNA methylation
research in PCa, as well as the other cancers, include 1) the identification of CpG
island hypermethylation of specific gene as a marker to identify cancer cells from
biological samples, eg, serum and urine; 2) the identification of CpG island
hypermethylation of specific gene as prognostic factors; 3) the iidentification of
dormant tumor suppressor genes can be reactivated by DNA demethylating drugs,
with the aim of reversing the neoplastic phenotype.
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PMP24, IDENTIFIED BY MSRF, UNDERGOES DNA
HYPERMETHYLATION ADSOCIATED 
GENIE SILENCING
DURING PROSTATE CANCER PROGRESSION
ABSTRACT
Transcriptional silencing of antitumor genes via CpG island methylation
could be a mechanism mediating prostate cancer (PCa) progression from an
androgen-dependent to an androgen-independent state. We have used the
ethylation-2ensitive restriction fingerprinting (MSRF) technique to identify novel
CpG-rich sequences that are differentially methylated between the genome of the
androgen-dependent PCa cell line LNCaP and that of an androgen-independent
subline LNCap generated by maintaining LNCaP in medium with charcoal-
stripped (CS) serum for over 30 passages. One such sequence identified was
located on a 5' CpG island that was found to span part of the promoter , exon 1
and part of intron 1 , of the roxisomal mbrane Pro tein 24 KD (PMP24) gene.
Using semiquantitative RT -PCR and bisulfite genomic sequencing, we established
an inverse relationship between mRNA expression and methylation of the 5' CpG
island of PMP24. PMP24 mRNA was absent in LNCap and tile androgen
receptor-negative PC-3 cell line; both exhibited dense methylation in the said CpG
island. In contrast PMP24 mRNA was expressed in LNCaP and normal prostatic
epithelial cells (NPrECs) whose PMP24 5' CpG island remained unmethylated.
Treatment of LNCap and PC-3 with the demethylating agellt 5-aza-
deoxycytidine (5-AZAdC) reactivated PMP24 mRNA expression. Transient
f:.
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transfection of PMP24 into LNCap and PC-3 cells induced a significant
reduction in cell growth and soft-agar colony formation potential , suggesting that
PMP24 gene product has antitumor properties. These results demonstrate the
utilty of MSRF in the identification of novel, differentially methylated DNA
sequences in the genome and suggest that hypermethylation-mediated silencing
of PMP24 is an epigenetic event involved in PCa progression to androgen
independence.
INTRODUCTION
Prostate cancer (PCa) is currently detected by routine screening of serum
levels of Erostate pecific ntigen (PSA) in males over 50 years of age (Newling,
1996). Early-detected tumors are usually confined to the gland and potentially
curable with radical prostatectomy and/or radiation. In cases of locally advanced
and metastatic disease, the front- line androgen ablation therapy results in an initial
stabilization or regression of the disease in approximately 80% of patients.
However, within 12-18 months , almost all tumors become refractory to androgen
ablation therapy, and to date effective curative treatments are lacking for these
tumors. Therefore , understanding the molecular basis underl ing the progression
of these cancers to androgen independence has long been an important objective
of PCa research.
Tumor initiation and progression have traditionally been viewed as a
process,involving the stepwise acquisition of multiple genetic alternations such as
rearrangements, losses, or duplications of chromosomal regiions and mutational
activation of oncogenes or inactivation of tumor suppressor glenes. However
mounting evidence indicates that "epigenetic" events, Le. , heritable changes in
:;1.
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DNA modification and chromatin structure without alterations in nucleotide
sequence are equally central to the evolution of cancer (Bayllin and Herman
2000a; Jones and Laird, 1999). In recent years, DNA methylation content, level,
and pattern have been shown to be an important epigenetic change commonly
associated with tumorigenesis (Baylin and Herman, 2000c; Jaenisch and Bird,
2003; Jones and Takai , 2001 b). Compared with their normal counterparts, tumor
cells often exhibit global hypomethylation of their genome but focal
hypermethylation of CpG-rich, regulatory sequences in genes with antitumor
functions (Laird and Jaenisch , 1996). Such CpG-rich clusters , called CpG islands
have recently been defined more stringently (Jones and Takai , 2001a). Among all
the putative CpG islands in the human genome, some are located in the 5' end of
the gene , including the promoter region , the first exon , the first intron , and
sometimes the second exon of the genes. These sequences are often referred to
as promoter regulatory CpG islands (Jones and Baylin , 2002b). While generally
unmethylated in normal cells, they become abnormally hypermethylated in cancer
cells , and these epigenetic alterations are frequently associated with
transcriptional silencing of their cognate genes.
Transcriptional silencing of an increasing number of genes in the prostate
cancer or in PCa cell lines are now known to be associated with hypermethylation
of their 5' CpG regulatory sequences. These genes include 
RARj32 (Nakayama et
aI. , 2001), ER-a (Lau et al. , 2000b), pS2 (Lau et a/. , 2000a), androgen receptor
(Jarrard et a/. 1998; Nakayama et a/. , 2000a), AR-associated protein 70 (ARA70,
(Tekuret a1. 2001c)), y-glutamyltransferase (GMT (el Yaagoubi et aI. , 1998)), 
cadherin (E-cad (Graff et aI. , 1995)), P-cad (Jarrard et aI. , 1997b), RADSF1A
(Kuzmin et aI. , 2002), p16 (Jarrard et aI. , 1997a), glutathione- transferase-
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(GSTPi (Un et aI., 2001 b; Nelson et aI. , 1997; Singal et aI., 20(1), 
p14!RF (Esteller
et aI., 2000a), 
iP1 (Kibei et aI. , 2001), progesterone receptor (Lau et aI., 2000c),
caveolin- and a-subunit of inhibin (Schmitt et aI., 2002), and 
CD44 (Lou et aI.,
1999; Verkaik et aI. , 1999). The biological roles of these genes are 
diverse; they
are all involved in the regulation of basic homeostatic cell mechanisms such as
cell cycle regulation, cell-cell interaction, protectio
against oxidative damage, or
tumor suppression. Collectively, these findings strongly support the hypothesis
that this epigenetic mechanism plays a critical role in the 
genesiis and/or
progression of PCa.
It is now well recognized that recurrent PCa is a spectrum of diseases that
differ in clinical presentation and prognosis (Catalona, 1994; Scher et aI., 1995a;
Scher et aI. , 1995b). It is therefore unlikely that a single modell 
iis sufficient to
represent all the genetic and/or epigenetic alterations in PCa progression. LNCaP
is one of the few human PCa cell lines that have retained androgen receptor (AR)
and androgen responsiveness (Taplin and Ho, 2001). Androgen-
independent
sublines have however been derived from LNCaP by maintaining LNCaP in a
hormone-depleted (charcoal-stripped) medium for many passages (Robbins et aI.,
1996; Singh et aI., 2003). One of these sublines, referred to here as LNCap
, is
androgen-independent and is a suitable model for studying androgen-
independent
PCa growth.
In this study, we employed a technique known as.methylation-
2ensitive
restriction fingerprinting (MSRF) (Huang et aI., 1997f) for the identification of
specific sequences whose methylation status changed from "
unmethylated" or
hypomethylated" in the androgen-dependent LNCaP cells to "
hypermethylated" in
the androgen- independent LNCap cells. Among an initial pool of over 
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candidates who exhibited this methylation status change, we selected candidates
that are located in the 5' regions of known genes. Transcript expression studies
were then conducted to identify those sequences whose cOglnate genes are
down regulated or suppressed in LNCap compared with LNCaP. Conjointly,
these selection criteria allowed us to identify genes that exhibited both loss of
expression and increased methylation in their 5' CpG-rich regulatory sequences in
LNCap compared with LNCaP. One such sequence identified by MSRF was
located to a putative 5' CpG island of the roxisomal mbrane Erotein 24 
(PMP24) gene (AL050349, (Reguenga et aI. , 1999c)), as predicted by
computational analyses. Primer extension analyses confirmed that this CpG island
encompasses part of the promoter, exon 1 , and part of intron 1 of PMP24. Using
semi-quantitative RT -PCR and bisulfite genomic sequencing" we established an
inverse relationship between PMP24 mRNA expression and hypermethylation of
the 5' CpG island of the gene. Treatment of LNCap with the demethylating
agent 5-aza- deoxycytidine (5-AZAdC) reactivated PMP24 mRNA expression.
Transient transfection experiments further suggest that PMP24 exerts antitumor
action in LNCap , but not in LNCaP cells. Collectively, our results demonstrate
that MSRF is useful in screening for altered methylation patterns among different
cellular genomes and in the isolation/identification of specific sequences
contributing to these changes. They further indicate hypermethylation-mediated




Cell Culture and 5-AZAdC Treatment
All prostate cancer cell lines except LNCap were purchased from A 
TCC
(American Type Culture Collection, Manassas, VA). All culture medium contained
1 mM sodium pyruvate, 0. 1 M non-essential amino acids, 100 U/mL penicilln, 100
f.g/ml streptomycin , 0. 05 mM -mercaptoethanol (Gibco BRIL, 
Carlsbad, CA), and
1 % insulin-transferrin-selenium (BD Biosciences, Bedford, MA). PC-3 and DU145
cells were maintained in Dulbecco s minimum essential medillm/F-
12 (DMEM/F-
12) supplemented with 5% charcoal-stripped (CS, steroid-depleted), heat-
inactivated fetal bovine serum (HI-FBS) (Sigma, St. Louis, MlO). LNCaP, an
androgen-dependent human PCa cell line, was grown in RPMII-
1640 medium with
25mM HEPES , 2mM L-glutamine plus 10% heat-inactivated fetal bovine serum
(HI-FBS). LNCap was a generous gift from Dr. Brain Liu (Brigham and
Women s Hospital, Harvard Medical School , Boston , MA, USA). It is an androgen-
insenstitive subline derived from LNCaP by being maintainedl 
in RPMI-1640
medium with 10% CS-FBS instead of 10% HI-FBS for over 30 passages. All cell
cultures were incubated at 37 C in a 5% C02 humidified atmosphere. For 5-
AZAdC (Sigma) treatment , LNCap and PC-3 were seeded at a density of 10
cells/ml medium in 25-cm culture flasks, allowed to attach for 24 hours before the
treatment. Cells were subjected to a total of 8 days ' treatment during which
medium was changed every 4 days and 5-AZdC was added in aqueous solution
at a final concentration of 0.5 f.M or 0.75 f.M.
The primary culture of normal prostate epithelial cells (NPrECs) was
obtained from Clonetics-BioWhittaker , Inc. (Walkersvil , MD);: cells were
immortalized in our lab by the addition of a retroviral vector expressing HPV-
E6/E7 ORFs as described previously (Tsao et a\., 1995). This NPrEC cell line was
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grown on the recommended PrEGM medium supplied by Clonetics-BioWhittaker
Inc. Protein markers in these cells were characterized by immunocytochemistry
as described by Mobley et al. (Mobley et aI., 2003)
All the immortalized normal (HOSEs) and cancerous (OVCAs) human
ovarian surface epithelial cells were maintained as described by Syed et al. (Syed
et aI. , 2001 b). TSUPr1 , a bladder cancer cell line, was maintaiined as previously
described (Tekur et aI. , 2001 b). The breast cancer cell line MCF-7 was purchased
from ATCC. An immortalized normal breast epithelial cell line, MCF10A , was a
generous gift from Dr. Jinquiang Chen (Johns Hopkins Universiity, Baltimore, MD).
DNA Extraction and MSRF
Genomic DNA was extracted from cells with the DNeasy( Tissue Kit
(QIAGEN , Valencia, CA) and quantified by spectrophotometer. MSRF was
performed as originally described with some modification (Huang et aI. , 1997e). In
brief, 1 /lg genomic DNA was digested with Mse I alone or dOllble-digested with
BstU I and Mse I following the conditions recommended by the supplier (New
England Biolabs, NEB , Beverly, MA). Digested DNA (20-100 ng) was used in
each 20-/l1 PCR reaction containing 2 mM MgCb, 200 /lM dNTP, 5% (v/v) DMSO,
1 unit of buffered AmpliTaq Gold DNA polymerase (Perkin-Ellmer, Foster City, CA),
and 2 (Ci ((-32P) dCTP (3000 Ci/mmol; NEN, Boston , MA). The genomes were
analyzed by PCRs with various permuations of paired arbitrary primers chosen
from the following: Bs1, 5' AGCGGCCGCG; Bs11, 5' GAGAGGCGCG; Bs12 , 5'
GCCCCCGCGA; Bs13, 5' - CGGGGCGCGA; PCG03, CTCCCTCTCG; PCG04, 5'
TCCTTCCTCG. PCR was performed at the conditions as previously described
(Huang et aI. , 1997d), and the products were separated on 4.5% nondenaturing
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polyacrylamide gels which were dried and exposed to Kodak X-
OMAT AR film
(Kodak, New Haven, CT) to visualize the labeled PCR products as bands on the
radiograph. Candidate bands displaying the appropriate differential methylation
status among "control" and "comparative" cell lines were cut
" reamplified, and
cloned directly into pGEM-T Easy vector (Promega, Madison, WI) for sequencing.
The resulting nucleotide sequences were compared to GenBank using the BLAST
program. Computational predication of putative CpG islands was performed CpG
island searcher at http://cpgislands.usc.edu/.
3 RNA Isolation and RT-PCR
Total cellular RNA was isolated from various cell lines with Tri-
Reagent
(Sigma) according to the protocol provided by the manufacturer. RNA was
subsequently subjected to DNase treatment to ensure its purity. Total RNA (up to
20 Ilg) was incubated at 3J0C for 30 min with 2 U buffered RQ1 RNase-
free
DNase (promega), 100 U RNase inhibitor (Perkin-Elmer), and 5 mM DTT (Sigma)
in a 100-111 final volume. A standard phenol/chloroform extraction was then
performed , followed by precipitation for 1 hr at - C with 2.5 vol of 100% ethanol
and 0. 1 vol of 3 M sodium acetate. The RNA pellet was retrieved by centrifugation
at 10,000 g for 15 min, washed twice with 70% ethanol
, and finally dissolved in
diethylpyrocarbonate (DEPC) water. Multiple routine examinations were 
taken to
carefully measure the quantity and assess the quality of RNA samples as
previously described (Syed et a\. , 2001a). One Ilg of total cellular RNA was
reverse transcribed with the GeneAmp RNA PCR kit (Perkin-Elmer), and 2 III out
of 60 III resulting cDNA was used in each PCR. Intron-spanning primers were
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designed with the Primer3 output program (http://ww.qenome.wLmit.edu/ciq-
bin/primer/primer3.cqi, Whitehead Institute. Cambridqe. MA) . For amplification of
PMP24 from eDNA, the forward primer was 5'
ATCMCAGCCAGATCMCATGTAC- , and the reverse primer was 5'
GCCAATCTTGAGCCACAGC-3' (MWG Biotech , High Point, NC). In parallel
mRNA levels of two other peroxisome membrane protein genes, 
PMP22 and
PMP70 (Lauer et aI. , 1999a; Reguenga et aI. , 1999b), were analyzed. The
forward primer sequence for 
PMP22 (AF250136) amplification was 5' GGT GGG
CCT CTG AGA TAT GC- , and the reverse primer was 5' - TGA TGA GGA AGA
ACA ACA TGA GG- . For human PMP70 (XM 010507) ampllification, the sense
primer was 5' - GCT T M ACT GTG CTT CCG AGT MG G-3." and the antisense
primer was 5' - GGA AT A GCC CAG AA CM CCA AG- . Hot-start PCR was
performed by heat activating AmpliTaq Gold DNA polymerase (Perkin-Elmer) at
C for 10 min. Optimized cycling condition was 36 cycles (for 
PMP24) or 30
cycles (for PMP22 and PMP70) 
of denaturing (94(C for 30 see)" annealing (56(C
for 30 see) and extension (72(C for 60 see), followed by a 10-min final extension.
Amplification of the correct sequences was verified by direct DNA sequencing of
PCR product at the Nucleic Acid Facility of University of Massachusetts Medical
School. Human 18S ribosomal RNA was amplified from cDNlA as a loading
control as previously described (Tekur et aI. , 2001a).
3.4'!apping of the Transcriptional Start Site
Two antisense primers, PE1 , 5' GACTACGAGCAGATCCCTTAGCTG-
and PE2, 5' CAGGGTCGGGGTTAGGMCTGTMG- , were designed
complementary to position 16-39 and -40--16 relative to the translational start site
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respectively. To label the primers, 10 pmole of each primer was incubated with 30
(Ci (y_ p) ATP (3000 Ci/mmol; NEN) and 20 U T4 polynucleotide Kinase (PNK
NEB) in 1X T4 PNK buffer in a total volume of 101-1 at 3rC for 30 min followed by
2 min of inactivation at 90 C. The labeled mixture was diluted to a final
concentration of100 fmol/Ill by adding 901-1 of DEPC water, and 1-1 
labeled
primer was used in each extention reaction. In a 10-1-1 reaction mixture, 151-g of
total RNA extracted from primary NPrEC, which expresses 
PMP24 mRNA, was
annealed with labelled PE1 
or PE2 in 1X First Strand Buffer(50 mmol/Ill Tris-
HCI; pH 8. 75 mmol/Ill KCI , 3 mmol/Ill MgCh) at 60 C for 20 min followed by 10
min at room temperature. The annealed mixture was mixed with 10 1-1 of 
reaction
buffer (50 mmol/Ill Tris-HCI; pH 8.3, 75 mmol/l KCI , 3 mmol/ll MgCh, 50 mmol/I
dithiothreitol (DTT), 1 mmol/l dNTPs) and 200 U of SuperScript II RNase H-
reverse transcriptase (Invitrogen , Carlsbad, CA), and incubated at 4rC for 60 min.
The reaction was stopped by the addition of 20 1-1 loading buffer. A total of 10 1-1 of
the samples was resolved by 6% denaturing polyacrylamide gel electrophoresis.
The same reactions without total RNA were carried out in parallel as negative
controls. As a size standard, genomic DNA from NPrEC was amplified with 
PE1
and PMP24seqF3 (5' - CTCCCTGTATCATCACCTGTCG -
, -
410- 389 nt). A
sequencing reaction was carried out for PCR product using 
labelled PE1
primer and loaded next to the primer extension product. The gel was then dried




One f.g of genomic DNA from various cell lines as 
weill as two normal
prostate tissue samples was modified with sodium bisulfite 
Ilsiing CpGemone 
DNA Modification Kit (Intergen , Phurcase, NY) following manufacturer
s instruction.
Modified DNA was finally dissolved in 25 f.L TE (10 mM Tris/O.
1 mM EDTA, pH
5) and used immediately or stored at - C until use. Two lL of modified DNA
was used in nested PCR for bisulfite sequencing. Primers fm amplifying
completely converted DNA were designed with Primer3 applying the criteria
described by (Grunau et aI., 2001). First PCR was performedl using forward
primer PMP24BS-F1 (5' TGAATTTAATATGGTTTAAGGGAAGTGTT-
) and
reverse primer PMP24BS-R1 (5' CACAAAATAAAATAACTAACCCAA-
Primers for nested PCR were 
PMP24BS-F2 (5'
GAGTTTATTGTGATTGGTTATAAGTTTTTT-
), forward, andl PMP24BS-R2 (5'
CAAACAACCAACTACAATTA- ), reverse. Both 
PCRs were
performed at the condition of initial hot-start at 95
C for 10 min , 40 cycles of
denaturing (94 C for 30 see), annealing (50 C for 30 see) and extension (72
C for
60 see), followed by a 10-min final extension. PCR product was extracted from
agarose gel with QIAquickCI gel extraction kit (QIAGEN) and cloned into pGEM-
Easy vector (Promega); 8 - 10 clones were picked for each celli line for
sequencing.
6 Plasmids, Transient Transfection, and Soft-agar Assay
The full- length PMP24 cDNA was amplified by PCR 
usiing forward primer:




GCA rTA ATT GGA GGG ACG G - . The PMP24 expression plasmid (pTriEX-
PMP24) was constructed by cloning the full-length cDNA into pTriEX-
1 vector
(Novagen, Madison, WI). The PMP24 open reading frame was confirmed by
sequencing in both directions. Transient transfection of LNGaP, LNCap
, and
PC-3 cells were performed with LipofectAMINE PLUS Reagent (Life Technologies,
Inc, Rockville, MD) according to manufacturer s instruction. \For monitoring
transfection efficiency in these three cell lines, 1 x10 cells were transfected with 
Ilg pCMV-I3-Galactosidase control vector (Progema) in a 6-well plate. Cells
transfected with pCMV-I3-galactosidase control vector and expressed 13-
galactosidase were visualized by microscoPY. In brief, after transfection the cells
were fixed in glutaraldehyde solution for 15 min , extensively washed in PBS 
1 X
buffer, and incubated with 0.2% X-Gal solution in PBS containing 2 mM 
MgCI2, 5
mM Fe(CN)63H 0 and 5 mM K Fe(CN)6. The cells that appeared blue after
fixation and incubation with X-Gal were counted to estimate effciency of
transformation. After establishing the transfection efficiencies, LNCaP, LNCap
and PC-3 cells were transfected with 1 Ilg of either the PMP24-containing vector
(pTriEX-PMP24) or the empty vector (as control). 1 x 10 ceilis were plated in 6-
well plates and allowed for attachment in serum-supplemented medium for 24
hours. Approximately 60-80% confluent cells were transfected in serum-
free
medium for 3 hours at 3JDC 
and incubated with complete medium for 48 hours.
The cells were harvested by scraping, washed with PBS, pelleted, and counted on
a hemocytometer. The same transient transfection experiment was repeated in
LNCapcs and PC-3 cells. Twenty-four hours post-transfectiion" cells from each
culture were seeded at low density (500 cells/plate (100 mm), four plates per sample)
in 0.3% agar in complete medium on top of an underlayer of 0.
6% Noble agar with
;);;,.
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complete medium (Salmon et aI. , 1978). Plates were incubated for up to 4 weeks.
Numbers of colonies growing on soft-agar plates were scored to establish the soft-
agar colony formation frequency, expressed as number of 
coloniles/100 cells plated).
4. RESULTS
2.4. Identification of a CpG-rich sequence located in the' 
5' region of PMP24
that exhibits differential methylation status among LNCaP. LNCapCs and
other androgen-independent PCa eel/lines.
To identify novel CpG-rich DNA sequences that are differentially methylated
between the androgen-dependent LNCaP and androgen-
independent LNCap
we performed comparative MSRF using genomic DNA isolated from LNCaP and
LNCapcs (Figure 1). In addition, we have exposed LNCap cells to HI-
FBS for
4 passages in order to determine whether steroid depletion-
induced methylation
changes in specific DNA sequences could be easily reversed! by short-
term
exposure to full serum. As additional controls , we included genomic DNA from
two other androgen-independent PCa cell lines, PC-3 and DU145, for comparison.
Genomic DNA isolated from different cell lines was subjected! to 
Mse I restriction
digestion. Since the restriction site of 
Mse I is TTM, which iis rare in CG-rich
regions, cellular DNA were digested into small fragments whiile most of the CG-
rich regions remained intact. The 
Mse digested DNA from each cell line was
then subjected to digestion with 
BstU I, a methylation-sensitive restriction enzyme.
Short DNA sequences with methylated 
BstU I sites were left uncut and amplified





Figure 1. MSRF analysis of genomic DNA isolated from androgen-
dependent and androgen-independent prostate cancer celli lines and one
bladder cancer cell line.
A. A schematic diagram depicting expected results. In this comparison
, the
methylation status was defined by comparing androgen-
independent (AI) cell lines,
Including LNCap , PC-3 and DU145, to the androgen-
dependent (AD) LNCaP .
When a BstU I site in a CpG-rich DNA sequence is methylated and protected from
digestion, DNA wil be amplified by the following AP- PCR. The single 
Mse 
digestion served as PCR positive control. B. A section of an autoradiograph from a
high-resolution gel analysis of DNA fragments obtained from MSRF analysis.
Candidates" refer to cellular DNA fragments with differentially methylated BstU 1
sites between the androgen-dependent LNCaP and the androgen-
independent
LNCap , PC-3 or DU145 cells. Candidate 1 is considered hypermethylated in
androgen-independent (AI) PCa cells when compared with androgen-
dependent
LNCaP cells, while Candidate 2 is recognized as a hypomethylated sequence in
the androgen-independent cell lines. The methylation pattern found in the
LNCapcs cells was not readily reversible by short-term exposure (2-
3 passages) of









methylated BstU II sites
no change in





'" ,, '" 
(Jti CJ f1 
.$' 
II II r- r- r-
+ ++ ++ - + - -  -
Mse 
BstU 
No BstU I site Of no cha nge
in methylation sta1t among







sites were digested and yielded no PCR products. The PCR products were size-
fractionated in high-resolution polyacrylamide gels along with PCR products
obtained from Mse 
digested (single enzyme-digestion) genomnc DNA serving as
a PCR positive control. Figure 1A is a schematic ilustration showing the expected
results when a CpG-rich sequence in androgen-independent cell lines (LNCap
PC-3 and DU145) is methylated but unchanged, not methylatedl
, hypermethylated,
or hypomethylated, compared with status in the androgen-
dependent (AD) LNCaP
cells. In a section of a ' real' autoradiograph (Figure 1A), shown as examples, are
two DNA sequences that are differentially hypo- (Candidate 11) or 
hyper-
(Candidate 2) methylated at their 
BstU I sites in LNCap (Lanes 1 & 2) or the
other androgen-independent (AI) cell lines (PC-3 or DU145) compared with
LNCaP (Lanes 5 & 6). The altered methylation patterns in these sequences 
are
permanent and not easily reversible by short-term exposure of LNCap
cells to
full serum (Lanes 3 & 4).
Twelve PCRs were performed with different permutatio
of primer pairs
selected from a set of 6 arbitrary primers in order to "
screen" a significant portion
of the genome for differentially methylated sequences between LNCaP and the
androgen-independent cell lines. Once confirmed with multiple rounds of 
PCR
and gel electrophoresis, the bands of interest (those representing
hypermethylation in androgen-independent cell lines compared with LNCaP) were
isolated from the gel , DNA eluted, reamplified by PCR with the same pair of
arbitrary primers used in the original PCR, cloned, and sequenced. BLAST and




From our MSRF screening, we identified 50 candidate sequences that
exhibited possible changes toward hypermethylation in LNCap
cells compared
with their status in LNCaP cells. Among these, we further selected candidate
sequences that belong to promoter regions and/or 5' regions of known genes as
priority candidates for further investigation. Among this short list
, we specifically
focused on candidates whose cognate genes were down 
regulated or silenced in
LNCapcs compared with their expression in LNCaP 
determiinedl by
semiquantiative RT -PCR. This approach aimed to 
identify novel genes that might
be silenced by hypermethylation of their 5' CpG-rich sequences in LNCap
cells
compared with LNCaP cells.
Among the short list of priority candidates, we identified a 125-
bp DNA
fragment that was judged by MSRF analyses to be hypermethylated in LNCap
and PC-3 compared with LNCaP (Figure 1B, candidate 1). 
BlADT search
indicated that the sequence composition of this fragment exactly matched intron 
of a previously known gene, the 
PMP24 gene (AL050349) (Fiigure 2A).
Computational sequence analyses showed that the identified intron 
1 is part of a
putative 625-bp CpG island in the 5' end region of 
PMP24 with a GC content of
68% and an observed/expected CpG ratio of 0.
79.
To characterize the composition of the putative CpG island of 
PMP24
primer extension analysis was performed using total RNA isolated from primary
culture of NPrEC cells, which expresses 
PMP24 mRNA, to map the transcription
start site (TSS) of PMP24 
mRNA. One antisense extension primer PE1 
was
designed complementary to position 16-39 relative to the translational start site.
Another primer, PE2, 
54 bp upstream of 
PE1, stretching from -40--16 nt , was also





Figure 2. Physical map of the 5' end of human PMP24 glene.
A The initial candidate DNA sequence, identified by MSRF analysis of LNCaP and
androgen-independent PCa cell lines (LNCapcs and PC-3), is aligned by Blast
search to a sequence in intron 1 of the gene (the dotted-line segment). 
indicates the BstU I sites that might be differentially methylated between LNCaP
and LNCap . The hatched box represents the 5' untranslated region, and exon 
is the open rectangle. Each vertical line represents a CpG dinucleotide. The
underscored segment represents the putative CpG island encompassing part of
promoter, exon 1 and part of intron 1. The double- lined region is the fragment
amplified by nested PCR for subsequent bisulfite modification (see Figure 4). B
The transcriptional start site (TSS, bent arrow) was mapped to nt -67 upstream of
the ATG start site by primer extension analysis. Single 
bandl was obtained with
either primer PE1 or PE2, 
in the presence (lane marked as +) or absence (lane
marked as -) of total RNA obtained from primary culture of NPrEC, which
expresses PMP24 mRNA. These two bands were exactly 54 bp apart according




















fragment was obtained by PE1 primer in the presence of total RNA from NPrEC
(Figure 2B , lane +), which was absent in the sample without RNA (Figure 8B , lane
-). The primer extension reaction using PE2 produced a fraglment exactly 54 bp
smaller than the PE1 extension product , according to the sequencing reaction
using labelled PE1 primer run next to the extension products on the gel , thus
confirming the specificity of the primer extension products. The TSS was therefore
mapped to 67 bp upstream from the ATG start site, indicating that the putative
CpG island of PMP24 gene actually encompasses part of the promoter, exon 
and part of intron 1 of the gene as shown in Figure 2A.
2 Specificity of transcriptional inactivation 
of PMP24 in androgen-
independent PCa cell lines
We next measured the levels of PMP24 
mRNA using semiquantitative RT-
PCRto determine 1) whether silencing of PMP24 transcription in LNCap (Figure
3A, lane 1 from the left) compared with LNCaP (Figure 3A, lane 3) is gene- and
PCa-specific and 2) whether the change could be easily reversed by exposing
LNCap to full serum for 3-4 passages (Figure 3A , lane 2). PMP24 mRNA was
absent from LNCap and PC-3 cell lines but was expressed in LNCaP, DU145,
primary cultures of NPrEC (Figure 3B), and immortalized NPrEC (data not shown).
In parallel , we had quantified transcript levels of two other known peroxisomal
membrane protein genes PMP22 and PMP70, in order to establish that the loss of
PMP24 expression is gene-specific. Messenger RNA levels. of PMP22 and
PMP70 in all PCa cell lines examined were comparable (Figlure 3A).
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Figure 3. RT -PCR analyses of levels of PMP24, PMP22, and PMP70
transcripts among the various cell lines.
A Expression of transcripts of 
PMP24, PMP22 and PMP70 among PCa cell lines.
Total RNA was extracted from an androgen-dependent prostate cancer cell line:
LNCaP, LNCap , PC-3 and DU145, and LNCap
exposed to heat-inactivated
fetal bovine serum (HI-FBS) for 3-4 passages. RT -PCR was performed with
crossing-intron primers to amplify transcripts. B Expression of 
PMP24 mRNA
among prostate, PCa, and non-prostate-derived cell lines. High cycle number RT-
PCR was performed in primary cultures of NPrEC, PCa celilines (LNCaP, DU145,
LNCapcs , and PC-3), a bladder cancer cell line TSUPr1 , immortalized normal
human ovarian surface epithelial cell lines (HOSEs), ovarian cancer cell lines
(OVCAs), the non-malignant breast epithelial cell line MCF-10A, and the breast
cancer cell line MCF-7. C Reactivation of PMP24 
expression in LNCap and PC-
3 cells with the treatment of 5-AZdC. Cells were treated with 0.
5 11M and 0.75 11M
AZAdC for a period of 8 days, respectively. Untreated 
andl treated cells were
used to extract total RNA for RT -PCR analysis. Human 18s rRNA was used as an
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We then determined whether silencing of PMP24 transcription is specific to
certain PCa cell lines including LNCap (Figure 3B). Using higlh cycle number
RT - PCR, we confirmed the absence of PMP24 mRNA in LNICap and PC-3 cells
and showed the presence of this transcript in immortalized normal human ovarian
surface epithelial (HOSE) cell lines , ovarian cancer (OVCA) cell lines, the
nonmalignant breast epithelial cell line MCF-10A , the malignant breast cancer cell
line MCF- , and a bladder cancer cell line, TSUPr1 (Figure 3B)..
2.4.3 Demethylation reactivated PMP24 transcript expression in LNCap
and PC-3 cells
Both LNCap and PC-3 showed no detectable or onl trace amounts of
PMP24 mRNA expression. After 8-day treatment of LNCap and PC-3 with 0.
flM or 0.75 flM 5-AZAdC PMP24 mRNA was re-expressed iin these two cell lines
(Figure 3C). On the contrary, 5-AZAdC treatment did not vary the level of PMP24
mRNA expression in LNCaP , which already expressed PMP24 mRNA prior to the
treatment (data not shown).
2.4.4 Characterization of methylation status of the putative CpG island 
PMP24 in LNCaP and androgen-independent PCa cell lines
MSRF results only revealed the methylation status of the BstU I sites within
the original arbitrary-primed PCR product, which , in the case of PMP24 aligned to
a region in its intron 1. However, the putative 5' CpG island of PMP24 gene
encompasses part of the promoter, exon 1 , and intron 1. To reveal the






the bisulfite genomic sequencing technique (Clark et aI. , 1994; Frommer et aI.
1992) to fully characterize this region. Bisulfite treatment of DNA specifically
converts unmethylated cytosine residues, but not 5-methylcytosine (5mC), to
uracil by deamination (Hayatsu et aI. , 1970; Wang et aI., 1980). When bisulfite-
modified DNA is subjected to PCR, uracil residues are amplified as thymine and
unmodified 5mCs as cytosines. Two pairs of primers were specially designed
complementary only to the completely converted DNA to perform nested-PCR to
amplify most of the putative CpG island (Figure 8A) after bisulfite modification of
genomic DNA. The amplified products were then cloned , and 8,-10 clones were
sequenced to reveal the methylation status of 43 CpGdinucleotides in the CpG
island of PMP24 in each genomic sample (Figure 10).
Bisulfite genomic sequencing analyses revealed the methylat~on status of all 43
CpG dinucleotides in a 573-bp fragment of the putative 5' CpG island of PMP24 
primary NPrEC, LNCaP , LNCap , PC-3, and DU145 (Figure 10). Our data
showed that almost all 43 CpG dinucleotides in the CpG island of PMP24 were
methylated among the clones derived from DNA obtained from PC-3 and
LNCap cell lines. In contrast , the 43 CpG sites in the 5' CpG island of PMP24 
primary NPrECs (Figure 10 , top panel) and normal prostate tiissues (unpublished
data; not shown).were mostly unmethylated, with a few sporadic 5mCs in some of
the clones. Interestingly, clones derived from DNA of LNCaP cells exhibited great
heterogeneity; the CpGs in some of the clones were heavily methylated while in
others were sparsely methylated. There was also a trend of decreasing
methylation frequency towards the 3' end of the CpG island. Siimilarly, PMP245'
CpG island in DU145 also exhibited heavy but incomplete methylation. Combined
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Figure 4. Bisulfite genomic sequencing analysis of PMP24 5' CpG island
methylation status in NPrEC and various PCa cell lines.
The methylation status of individual clones of the 
PMP24 5' sequence containing
the putative regulatory CpG island in primary NPrEC and LNCaP , LNCap , PC-
DU145 PCa cell lines were analyzed. Each line represents one single clone from
direct cloning of 573-bp PCR product amplified from bisulfite-modified DNA from
the various cell lines. Each circle represents one of the 43 CpG dinucleotides in
this DNA fragment. Methylated CpGs are shown as filled circles and un methylated
ones as open circles.
il'
CHAPTER II
inverse relationship between the extent of methylation in this GpG island and
levels of gene transcription detected in the various cell lines.
2.4. 5 Ectopic expression ofPMP24 in LNCap and PC-
3 inhibited tumor cell
growth and soft-agar colony formation potential
To elucidate the functional role of 
PMP24 in PCa cells , we transiently
transfected a PMP24 expression vector into LNCap and PG-
3 cells. In a 4-day
culture experiment, forced expression of 
PMP24 in both cell lines resulted in
modest, but significant, decreases in cell number (27% and 36%, respectively;
Figure 11) compared with controls transfected with the empty vector. Furthermore,
transient transfection of LNCap and PC-3 cells with PMP24 
expression vector
also diminished soft-agar colony formation by 24% and 32%, respectively,
compared with cells transfected with empty vector.
5 DISCUSSION
Disruption of the normal methylation pattern is a common event in
tumorigenesis (Baylin and Herman, 2000b; Jones and Takai , 2001c). Cancer cells
showed distinct methylation changes that vary considerably between different
tumors, suggesting different degrees of influence exerted by methylation on the
transformation process (Liang et aI. , 1998c). For example, alterations in genomic
methylation pattern are quite prevalent in neoplasms of the colon and the bladder.
In prostate carcinogenesis, we are just beginning to recognize the influence
exerted by DNA methylation on the development and progression of the disease.
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Figure 5. Ectopic expression of the PMP24 gene inhibited growth in LNCaCS
and PC-3 cell lines but not in LNCaP cells.
Transient transfection of pTriEX-PMP24 into LNCaP, LNCap " and PC-
3 cells
was performed using LipofectAMINE and PLUS Reagent according to the
manufacturer s instruction. Both LNCap and PC-3 cells showed a significant
decrease in cell number (upper panel: cell counts) following forced expression of
PMP24 mRNA, confirmed by RT -PCR detection , 48 h after transfection (lower
panel: mRNA expression). The cell number decreases are 2:7% (Pc:0.005) and
36% (Pc:0.005) in LNCap and PC-3 cells, respectively.
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silencing of tumor suppressor genes and other key cellular regulatory genes is a
major epigenetic change associated with oncogenesis in this organ. As
exemplified in the current study, progression of PCa from an androgen-dependent
state to an androgen-independent state may involve DNA methylation-medieated
silencing of specific regulatory genes that could be identified , in an unbiased
manner, using MSRF (Huang et aI. , 1997c). The current study is first to apply this
technique to identify genes that are involved in PCa progression. PMP24
previously not known to be associated with PCa or other cancers, was identified
for the first time as a gene regulated by DNA methylation and further shown to
exhibit putative antitumor action.
MSRF was first described by (Huang et aI. , 1997b). Other similar
techniques such as methylation-sensitive arbitrarily primed PCR (MS AP-PCR)
(Gonzalgo et aI. , 1997) and methylated CpG island amplification (MCA) (Toyota et
aI. , 1999a) were developed about the same time in the late 90s. Subsequent
modifications to these techniques have recently been reviewed by (Davies , 2002)
and (Liang et aI. , 2002b). These methodologies hold the promise of providing a
rapid and effcient way to screen for changes in methylation patterns in genomic
DNA and to isolate specific sequences associated with these changes , in a
nonselective manner. Many attempts have been made but only modest success
have been achieved in identifying specific genes whose 5' CpG sequences
undergo methylation changes during tumorigenesis. Using MlSRF , (Huang et aI.
1997a) identified two hypermethylation-containing fragments, HBC- 1 (for
hypermethylation in breast cancer ) and HBC- , from DNA usolated from normal
and malignant breast tissues. Unfortunately, nucleotide sequence analysis did not
match HBC-1 to any known sequences in the GenBank database , whereas the
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sequence of HBC-2 matched the upstream region of an antisense WT1 (Wilms
tumor suppressor gene) promoter. (Kohno et aI. , 1998) used a similar technique
MS AP-PCR , to analyze genomic DNA from normal lung tiSSUIes and non-small
cell lung carcinoma cell lines and identified three DNA fragments containing CpG-
rich sequences that were mapped to chromosomes 4q34, 10q26, and 17p13.
p13. , respectively; these chromosomal regions were shown to be
hypermethylated in a subset of primary lung tumors 
in vivo. However, these CpG-
rich fragments have not yet been linked to any known gene. Liang 
et al. (Liang et
aI. , 1998b; Liang et aI. , 2000; Salem et aI., 2000a) used M8 AP-PCR and
identified a hypermethylated DNA fragment in a human colon tumor cell line. This
fragment matched part of a human 
pressed quence lag (EST) in GenBank,
and this unknown gene (TPEF) encodes a transmembrane protein containing EGF
and follstatin domains. The gene exhibits frequent loss of heterozygosity in
various tumors.
False positives are a major problem, resulting in the low yield of MSRF and
similar techniques (Davies , 2002; Liang et aI. , 2002a). In addition to the possibilty
of incomplete restriction digestion, this problem is compounded by the
heterogeneity of tumor tissues that commonly comprise mixtures of benign and
cancerous tissues expressing varying levels of the differentially methylated genes.
Therefore, in this study, we have chosen to use androgen-dependent and
androgen-independent LNCaP cell lines as a model to study the methylation
status changes during the progression of PCa from an androgen-dependent to an
androgen-,independent state. In addition, we included other two androgen-
independent cell lines , PC-3 and DU145 , in the MSRF screen. The candidates we
selected were those that exhibited hypermethylation in the LNCap subline as
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well as in one or both androgen-independent PCa cell lines. Another reason why
MSRF may have low yield is the many CG-rich sequences in the genome whose
role in gene regulation is stil unclear. For example, the presence of redundant
CG-rich elements such as LINE and Alu could be identified by this screening
method. Additionally, sequences located downstream of the pmmoter/5' regions
of genes are often identified (Liang et aI. , 1998a; Salem et at , 2000b), but their
role in regulation of gene expression has yet to be established. For these reasons
among the initial pool of 50 candidate sequences we focusedlon those that could
be localized to the promoter/5' end of known genes. Since the cognate genes
were known , we were able to immediately determine whether significant
downregulation or loss of expression of the cognate genes occurred in the
androgen-independent PCa cell lines compared with LNCaP. These combined
strategies of carefully selecting the model system and fiteringl the candidates have
helped us to identified genes relevant to this stage of PCa progression.
A CpG-rich fragment , which was un methylated in the androgen-dependent
LNCaP but methylated in androgen- independent LNCap as well as in PC-3 cells,
was identified and matched 100% to a region in intron 1 of PMP24. This region
was further identified as part of a 625-bp putative CpG island in the 5' region of
the gene by computational analyses of gene sequence. This putative CpG island
spans part of the promoter, exon 1 and part of intron 1. Using primer extension
analyses we were able to confirm the predictions from computational analyses.
The GC content in this CpG-rich sequence was found to be 68 %, with an
observed/expected CpG ratio of 0. 79. Loss of PMP24 expressuon was clearly
associated with close to complete methylation of this CpG-rich sequence in
LNCap and PC-3 cells. Together, these data indicated that this CpG-rich
''0
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fragment fulfills the criteria for a bona fide CpG island (Gardiner-Garden and
Frommer, 1987; Takai and Jones, 2002). Reactivation of transcription of 
PMP24
in LNCap and PC-3 cells by treatment with the demethylatingl agent 5-
AZAdC is
in accordance with the notion that 
PMP24 is silenced by hypermethylation.
However, more direct evidence is needed to definitively demonstrate a causal
relationship between 
PMP24 transcriptional silencing and hypermethylation of this
CpG island. For example, it is necessary to show that the putative 
CpG island
possesses promoter activity towards 
PMP24 transactivation" and hypermethylation
of this region abolishes its promoter activity. Such investigations are currently
ongoing.
Human PMP24, located in chromosome 20q11.21-13. 113, 
was first cloned
after its rat homolog protein was co-purified with the other two major peroxisomal
membrane components: PMP70 and PMP22 (Reguenga et aI., 1999a). The gene
is highly conserved among different species with two putative membrane-spanning
domains in the conserved region. The PMP24 protein showed no homology to any
existing protein motif, and its function remains unknown. Peroxisomes are small
(0.5 to 1. m) multipurpose organelles comprising a single membrane
surrounding a dense matrix of enzymes. Peroxisomal enzymes metabolize a
broad spectrum pf substrates, including long-chain fatty acids" sterols, cholesterol,
antibiotics, oxygen free radicals, and many other metabolites (Masters and Crane,
1998). Various endogenous and exogenous bioactive molecules are 
oxidized by
oxidases in the peroxisomes, thus generating large 
quantities. of hydrogen
peroxide, which are readily rendered harmless by the high levels of catalase in
these organelles. Unlike mitochondria, 
peroxisomes do not possess their own
genome, and all proteins are encoded by nuclear genes, 
syntlhesized on free
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cytosolic ribosomes, and imported posttranslationally into the organelle (Johnso
and Olsen, 2001). The peroxisome membrane serves several important functions.
First, it regulates importation of proteins from the cytosol into the organelle.
Second, it keeps the metabolically active enzymes and potentially harmful
byproducts inside the organelle. Last, members of the peroxiso
membrane are
known to be involved in the biogenesis of peroxisomes. Peroxisomal membrane
proteins (PMPs) are broadly classified into the Type I proteins (e.
g. Pex2p, Pex3p,
Pex15p and Pex16p) that are believed to playa role in peroxiisome biogenesis
and the Type II proteins (e.g. PMP22, PMP34 , PMP47 and PMP70) that are not
involved in the process (Bryant and Wilson, 1995; Eckert and Erdmann, 2003).
Peroxisomes divide by budding from pre-existing peroxisomes (Marshall, 1995),
and impairment of their biogenesis has apparently been linked to tumor
progressio . Although Type II PMPs are not involved 
in peroxiisome biogenesis,
posttranscriptional- or translational- reduction in PMP22 and PMP70 protein
expression has been shown to be associated with colon carcinogenesis (Lauer et
aI., 1999b). Our finding that forced expression of 
PMP24 in tw PCa cell lines
inhibited cell growth and soft-agar formation suggests that PMP24 has antitumor
function. However, the biological roles of PMP24 in peroxisome regulation and
carcinogenesis remain poorly understood and are currently under investigation.
Worth mentioning is the proximity of this gene to chromosome 20q13 (HPC20),
which has been reported to be linked to a prostate cancer susceptibility region.
Fine mapping revealed positive linkage scores spanning from 20pter to 20q11 in
subsets hf hereditary prostate cancer familes (Zheng et aI., 
2001). Localization of
PMP24 at 20q11.21-13. 13 raises the possibilty that complete loss of expression
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could be caused by a second "hit" caused by methylation-medi1ated silencing of
the gene in some PCa patients.
To our best knowledge, we are the first to report successful application of
MSRF in the identification of a methylation-regulating gene of known identity. The
identified gene PMP24 encodes a 24-KDa peroxisome membrane protein and
contains a bona fide CpG island. Hypermethylation of this CpG island in the 5'
region of PMP24 is associated with transcriptional silencing of the gene in PCa
cell lines, while forced expression of PMP24 appears to inhibit growth in specifc
androgen-independent cell lines. Taken together, these results suggest that
putative antitumor genes can be identified and isolated from PCa by virtue of their




METHYLATION OF A SPECIFIC CpG SITE OF AP- CIS-
ELEMENT IN INTRON 1 OF PMP24 IS ASSOCIATED WITH
GENE SILENCING IN ANDROGEN- INDEPENDENT PCA CELLS
ABSTRACT
Gene silencing during carcinogenesis may be caused by hypermethylation
of the promoter CpG island of a gene. DNA methylation associated gene silencing
can occur by steric interference of transcription factor binding! to the promoter. We
recently identified a novel gene, PMP24 , that undergoes DNA methylation
associated gene silencing specifically in prostate cancer cells. We investigated
whether PMP24 expression is repressed by disruption of transcription factor
binding to critical cis-element by hypermethylation of its promoter CpG island.
Using limited demethylating bisulfite sequencing analysis, a CpG containing AP-
cis-element in the intron 1 of PMP24 was found to be preferentiially demethylated
in androgen-independent (AI) LNCap and PC-3 treated with 5-aza-
deoxycytidine (5AZAdC). Electrophoretic Mobilty Shift Assay (IEMSA)
demonstrated that. in vitro methylation of the element disrupted the protein-DNA
binding. Furthermore , reporter assays showed that among the two CpG
dinucleotides of the AP- cis-element the first CpG was critical for the protein-
DNA interaction and promoter activity of PMP24. Using methylated
oligonucleotides that introduce methylation specifically at AP-2 site in cellulo
demonstrated that methylation of AP-2 cis-element alone but not the whole CpG
island was sufficient for PMP24 repression. Interestingly, PMP24 silencing in
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androgen-dependent (AD) LNCaP cells showed no response to 5AZAdC
treatment, suggesting an alternative silencing mechanism for PMP24 in different
prostate caner cells. Our study is the first to report the silencingl mechanism for
PMP24 in AI LNCap and PC-3 by the complete methylation of a single CpG site
of AP- cis-element in the intron 1 of the PMP24 promoter CpG island, that
interferes with transcription factor binding.
INTRODUCTION
DNA methylation is widely involved in tumorigenesis and the changes in
both its level and pattern have been seen in virtually all types of cancers (Esteller
and Herman , 2002; Jones and Baylin, 2002c). Hypermethylation of promoter CpG
islands in cancer cells is of particular interest due to its close association with
gene silencing especially when the silencing occurs to tumor suppressor genes
such as breast cancer 1 , early onset gene (BRCA1) (Catteau and Morris, 2002),
mutL homolog 1 (MLH1) (Issa, 2000), p16 (Sarbia et a\. , 2004) etc. Reactivation of
these genes often can be achieved by reducing their promoter CpG island
methylation passively with chemical treatment (Dowell and Minna, 2004). The
reversibility of DNA methylation and its effect on the expression of genes,
particularly tumor suppressor genes, has made it an attractive therapeutic target
for cancer treatment (Baylin , 2004; Egger et a\. , 2004a). In fact, 5-aza-
deoxycytidine (5AZAdC, decitabine), a demethylating agent , has been tested in
severa ! clinical trials for the treatment of hematopoietic maliglnancies (Hennessy et
a\. , 2003; Issa et a\. , 2004a; Ravandi et a\., 2001b) and solid tumors (Momparler et
aI. , 1997a; Thibault et a\. , 1998b). However , extent of gene activation by 5AZAdC
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treatment was reported to be both cell type dependent and targlet gene dependent
(Farinha et aI. , 2004; Gupta et aI. , 2003), suggesting that reactivating
hypermethylation silenced genes by demethylating agent miglht not as simple as
we thought (Aparicio and Weber, 2002). A clear understanding of the mechanisms
of DNA methylation associated gene silencing can help us achieve better
implications on the therapeutic use of this group of agents such as target-specific
reactivation.
Promoter CpG islands located in the 5' regulatory reglion of the genes not
only encompass promoter but also often extend to exon 1 and untron1 region.
Hypermethylation of CpG islands is thought to repress gene transcription by
interfering with transcription initiation. Recent studies have liinked DNA methylation
related proteins such DNA methyltransferases (DNMTs) or methyl CpG binding
domain (MBD) proteins to histone modification proteins like histone deacetylases
(HDACs) (Karpf and Jones, 2002). These proteins facilitate the assembly of
repressive chromatin structures opto methylated DNA and make it inaccessible to
gene-specific transcription factors and/or general transcriptional machinery to
initiate transcription. In addition , DNA methylation can also directly affect gene
transcription by sterical interference of transcription factor binding to cis-element in
the promoter region (Muiznieks and Doerfler, 1994). It has been reported that
reduced binding at Sp1 element led to a decrease in the expression of
retinoblastoma (Rb) gene (Clark et aI. , 1997a) and p21(Cip11) gene (Zhu et aI.,
2003). Methylation of CpG dinucleotide in ETS binding site preventing
transcription factor binding was functionally important in the repression of Keratin
18 gene (Umezawa et aI. , 1997), but not sufficient for the repression of Surf-




correlation between methylation of specific CpG dinucleotide or CpG-rich regions
and the downregulation of the gene has also been demonstrated in the clinical
specimen for ER-r3 in PCa by our lab (Zhu et aI. , 2004c) and TP53 in acute
lymphoblastic leukemia (ALL) (Agirre et aI. , 2003). Accumulating evidences
suggested the existence of CpG dinucleotides within cis-elemellt whose
methylation status is crucial for the transcription of the gene.
In our previous study, we identified a novel gene, PMP24 , silenced in
androgen-independent (AI) PCa cells such as LNCap and PC-3. The gene
silencing is associated with hypermethylation of the promoter GpG island, which
encompasses part of promoter, exon 1 and part of intron 1 off PMP24 , and can be
readily reactivated by the treatment of 5AZAdC in these cells. In the current study,
we aimed to investigate if there is any cis-element in the promoter CpG island
whose CpG dinucleotide methylation is essential for the repression of gene
transcription. We hypothesized that the removal of methylation from critical 
cis-
element to resume the transcription factor binding is necessary to reactivate gene
expression by treatement with demethylating agents such as 5AZAdC. Therefore,
by bisulfite sequencing the promoter CpG island of reactivated gene after the
treatment with 5AZAdC, one should be able to identify such critical 
cis-element
subject to demethylation by the treatment. Using limited deme-thylating bisulfite
sequencing, we identified an activator protein 2 (AP- 2) cis-element in the intron 1
of PMP24 promoter CpG island preferentially demethylated wilen the gene was
reactivated by 5AZdC at a low concentration. We further demonstrated that the
first but not the second among the two CpG dinucleotides in the AP- cis-element
was essential for promoter activity and its methylation blocked DNA-protein




gene silencing. We later discovered that PMP24 is silenced in androgen-
dependent (AD) low passage LNCaP cells with its promoter CpG island heavily
methylated to the same extent as in AI LNCap and PC-3 with the exception of
incomplete methylation of the first CpG of AP-2 cis-element. Reactivation of
PMP24 in LNCaP can be achieved not by 5AZAdC treatment but by treatment with
Trichostatin A (TSA), a HDAC inhibitor, suggesting the silencing of PMP24 is
controlled by a different mechanism in the LNCaP cells.
3. MATERIALS AND METHODS
1 Cell Culture and Treatment
All prostate cancer cell lines were maintained as described (Wu and Ho,
2004c). All cell cultures were incubated at 37 C in a 5% C02 humidified
atmosphere. For 5-AZAdC (Sigma, St. Louis, MO) treatment" UNCaP , LNCap
and PC-3 were seeded at a density of 2x10 cells/ml medium in 25-cm culture
flasks , allowed to attach for 24-48 hours before the treatment. Cells were
subjected to a total of 5 days ' treatment during which medium was changed on
day 1 and day 4 and 5-AZAdC was added in aqueous solution at a final
concentration of 0. 1 11M , 0. 5 11M, 1 11M or 5 11M. ForTSA (Silgma) treatment alone
or in a combination with 5AZdC, TSA was added into med"um on day 4 at the
final concentration of 5 11M for 6 hr or 24 hr before cell harvesting.
\;c
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2 RT-PCR Analysis and Genomic Bisulfte Sequencing Analysis
Total RNA was extracted from the cells and subjected to RT-PCR analysis
for PMP24 expression as described previously (Wu and Ho" 2004b). Genomic
DNA extracted from the same set of the cells was bisulfite modified for genomic
sequencing analysis for PMP24 gene as described in Wu and Ho , 2004. For
prediction of putative transcription factor binding sites, a total 547 bp of PMP24
promoter CpG island, -195 to +352 relative to transcription starting site, was
subjected to computational analysis using Matlnspector (ww.aenomatix.
2 Electrophoretic Mobilty Shift Assay (EMSA)
The potential activator protein 2 (AP-2) cis-element and its neighboring
sequence (CTGTGTGAGTGGGGCCGTCGGGCCGGGCTG) were chosen to
synthesize 30-bp probe for EMSA analysis. Synthetic sense and antisense
oligonucleotides were 5' end- labeled with infrared fluorescence dye IRDye 800
(LI-COR Biosciences, Lincoln , NB). Wild type or mutated unlabeled
oligonucleotides as listed in Table 1 were synthesized (QIAGEN , Valencia, CA) as
competitors for analyzing binding specificity. Double-stranded probes were formed
before binding reaction by heating a mixture of sense and antisense
oligonucleotides at 95 C for 5 minutes and cooling down to room temperature
gradually. Methylated probe was generated by 
in vitro methylation of
oligonucleotides by Sss I methylase according to manufacturer's instruction (New
Englaritl Biolabs, NEB , Beverly, MA) Complete methylation ot the oligonucleotides
was confirmed by restriction digestion with methylation-sensutive BstU I (NEB)
before purification using QIAquick nucleotide removal kit (QIAGEN). Protein-DNA
binding reactions were set up with 5 \.g of nuclear extract from various cell lines in
Table 1. Oligonucleotide sequences for EMSA probes.








CTGTGTGAGTGGGGTT A TT AAGCCG1GGCTG
GA TCGAACTGACCGCCCGCGGCCCGTAP2 consensus




binding buffer (50 mM Tris-HCI , pH 7. 50 mM KC1, 5 mM MgCb, 0.01% BSA
1 mM DTT), 0. 5 IJI glycerol , 0. 5 IJI 20 mg/ml poly(d(I-C)) with or with out unlabeled
competitive oligonucleotides. After 10 minute incubation at room temperature,
50nM of IRDye labeled probes were added into each reaction and incubated at
room temperature for another 20 minutes in the dark before separation on the
native polyacrylamide gel. Gel was run in the dark for the desirable separation and
directly scanned on Odyssey Infrared Imaging System (LI-COR) in proper channel.
3.4 Construction of Luciferase Plasmids
Since the 5' UTR and part of the open reading frame (ORF) of PMP24 gene
was included in the luciferase plasmids to study their role on promoter activity, the
pGL3 basic plasmid (Promega, Madison , WI) was modified with the insertion of an
IRES (Internal Ribosomal Entry Site) in front of the luciferase gene to eliminate
any potential interference from the 5' UTR and ORF on the translation of the
luciferase gene and its activity. The modified plasmid was named as pGL3/1RES.
The DNA fragment that contains the region from nt -2042 to + 398 ( relative to the
transcription start site (+1)) of the human PMP24 gene, was. amplified from human
genomic DNA using primers: PMP24promF , GGTGGTACCGAACTCCTGGCTTC
(Kpn I) and PMP24promR AGACCTCGAGMTGTGCAGTGG (Xho I), modified
with Kpn I and Xho I site respectively. PCR was carried out with PlatinumCI Pfx
DNA polymerase (Invitrogen , Carlbad , CA) at the recommendled condition by
manufa,cturer to ensure high fidelity during long amplification.. The 2440-
amplified product was purified from the gel and double digested with Kpn I and
Xho I , and cloned into pGL3/1RES digested with same enzymes. From this
resulting plasmid , designated as pGL3/IRES/(-2042/+398), additional plasmids
-.-
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with various 5' end deletions of the PMP24 promoter including pGL3/1RES/(-
722/+398), pGL3/IRES/(-347/+398), pGL3/IRES/(-347/+161) and pGL3/1RES/(-
347/+262) were made either with specific restriction enzymes or using Delete-
Base kit (promega). Plasmids with mutations at either the first CpG or the second
CpG of AP- cis-element were generated from pGL3/IRES/(-347/+398) using
GeneTailer Site-Directed Mutagenesis System (Invitrogen) and named as
pGL3/IRES/(-347/+398)/mutCG1 and pGL3/1RES/(-347/+398)!mutCG2. The
orientation and sequence of each construct was confirmed by DNA sequencing
analysis (Macrogen , Seoul , Korea). In vitro methylation of pGL3/IRES/(-347/+398)
was carried out by Sss I methylase according to manufacturer s instruction (NEB)
and confirmed by restriction digestion with methylation-sensitive 
BstU I (NEB).
Completely methylated plasmid was purified using QIAquick nucleotide removal kit
(QIAGEN).
5 Transient Transfection and Luciferase Activity Assay
Transient transfection of LNCaP cells were performedl with LipofectAMINE
PLUS Reagent (Invitrogen) according to manufacturer s instruction. Briefly, 6 x10
cells were plated in 24-well plate (Nunc, Rochester, NY) and allOwed to attach for
48 hrs before transfection. Approximately 60-80%.confluent cells were transfected
in antibiotics-free medium without serum for 3 hours at 37 C vvth 0.2 J.g luciferase
plasmid together with 0.04 J.g pCMV-p galactosidase as internal control in
triplicate for each plasmid. Cells were then incubated with complete medium for 24
hours before the luciferase assay. Luciferase assay was carried out using Bright-
Glo luciferase assay kit (promega) following the manufacturer s instruction. Briefly,




After 5 min lysis , 75 IJL of cell lysate was transferred to 96-weU FluoroNunc
plate (Nunc) and reacted with same volume of reconstructed substrate buffer for at
least 5 minutes before subjected to luminescent reading in a Wallac 1420
Multilabel Counter (Perkin Elmer, Gaithersburg, MD). The other 25 IJL of cell
lysate was incubated with the same volume of 2 x I3-Galactosidlase enzyme assay
buffer at 37 C for 30 min before the absorbance was read at 420nm in a IJQuant
plate reader (Bio-Tek Instruments, Inc. , Winooski, VT). Relatiwe luciferase activity
of each well was normalized against its l3-galactosidase activity before averaging
the relative activities of triplicates.
Methylated Oligonucleotides Treatment
A 16-bp sequence was chosen for targeting the AP-2 cis-element.
Phosphorothioted (*) oligonucleotides with 5'-methylcytosinces (me) in CpG
dinucleotides, metAP-2 (G* G* mCGT mCGGGC mCGG* T), was synthesized
(Proligo, Boulder, CO). Unmethylated phosphorothioted oligonucleotide, ctrIAP-
was purchased (MWG Biotech , High Point , NC) and used as a negative control.
PMP24 expressing NPrEC cells (3 x10 ) were seeded in 6-well plate 24 hours
before the delivery of oligonucleotides. Transfections in duplliicate were carried out
by addition of 2 IJM of metAP-2 or ctrlAP-2 with 10 IJL Plus Reagent and 6 IJL of
Lipofectamine according to manufacturer s protocol (Invitrogen). Untreated cells
and transfected cells were harvested after 96 hours for RNA and genomic DNA
extraction using the standard protocols. The experiment was repeated once to





measure the expression level of PMP24 for each sample. Bisulfite sequencing
analysis was done for each sample as described previously (Wu and Ho, 2004a).
ChiP Assay
In vivo analysis of specific protein binding at its target site was performed
using ChiP assay essentially as described in Upstate ChiP protocol. Briefly, one
T -75 flask of control and TSA or 5AZAdC treated cells were f ed with 270IJL
formaldehyde into 10mL medium at 37 C for 10 minutes. Fixed cells were washed
with ice-cold PBS for 3 times and scraped into 10mL ice-cold! PBS. Cells were
then pelleted and resuspended in 2mL Cell Lysis Buffer (5mM PIPES , 85mM KCI
5% NP-40, protease inhibitor cocktail) and incubated on ice for 10 minutes.
Isolated nuclei were pelleted and resuspended in 650IJL Nuclear Lysis Buffer
(50mM Tris. HCI , 10m MEDTA , 1% SDS , protease inhibitorcoclktail) and incubated
on ice for 10 minutes. Chromatins were sonicated to sizes of 0.3 - 1.5 Kb on ice
by total 4 times of 20-second burst followed by 1 minute of cooling on ice with
Branson Sonifier 250. Sonicated chromatins were centrifuged at full speed for 10
minutes at 4 C to clear the debris. Supernatant was 1 :10 diluted with ChiP
dilution buffer ( 16.7mM Tris. HCI(pH8. 1), 1.2mM EDT A, 0.01 % SDS, 1. 1 % Triton
100, 167mM NaCI , protease inhibitor cocktail). Each sample was then pre-
cleared with 80IJL salmon sperm DNNprotein A agarose slurr at 4 C for 30
minutes with agitation. Two milliliter chromatin was saved as no antibody negative
control. Agarose beads were briefly pelleted and 500IJL supernatant was saved as
input positive control. Each cell sample was divided into 2mL each , one aliquote
was incubated with 2.51JL AcH3 antibody (Upstate), the other was incubated with
51JL AcH4 antibody (Upstate) at 4 C overnight with rotation. After antibody
#:.
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incubation , 251J1 salmon sperm DNNprotein A agarose slurry was added to each
sample and rotated at 4 C for another one hour. Agarose beads were then gently
pelleted by centrifugation and washed for 3-5 minutes on a rotating platform with
1 ml of each of the buffers listed in the order as follow: 1) Low Salt Wash Buffer
one wash (20mM Tris. HCI(pH8. 1), 2mM EDTA, 0. 1% SDS , 1% Triton X-100,
150mM NaCI), 2) High Salt Wash Buffer one wash (20mM Tns. HCI(pH8. 1), 2mM
EDT A, 0. 1 % SDS, 1 % Triton X-100 , 500mM NaCI), 3) LiCI Wash Buffer one wash
(10mM Tris. HCI(pH8.0), 1mM EDTA, 1% deoxycholate acid, 1% NP-40, 250mM
LiCI), 4) 1X TE two washes. Carefully washed beads were e Ulted with 100IJL
freshly prepared elution buffer (1 %SDS, 0. 1 M NaHC03) twce. 5M NaCI was
added to the eluate to the final concentration of 0.2M and reversed histone-DNA
crosslinks by heating at 65 C for 4 hours , including the input samples saved
previously. Each sample was digested with 401Jg/mL proteinase K (10nM EDTA
40mM Tris-HCI , pH 6.5) for one hour at 45 C before DNA was purified with
QIAquick PCR kit (QIAGEN). Eluted DNA was then used in PCR to amplify the
interested region.
4 RESULTS
1 CpG sites of AP-2 sis-element in intron were preferentially
demethylated by 5AZAdC treatment.
We used limited demethylating bisulfite sequencing to determine if there is
any critical CpG site in the PMP24 CpG island for its promoter activity. We treated
the cells with various concentrations of 5AZAdC and found that 0. 11JM is the
lowest concentration to activate silenced PMP24 in LNCap and PC-3. We
i u
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performed genomic bisulfite sequencing of PMP24 promoter CpG island for the
DNA extracted from PC-3 cells treated with various concentration of 5AZdC. We
found consistent results showing less demethylation in the cells treated with lower
concentration such as 0. 11JM as compared to higher concentration treatment such
as 51JM. In the lowest concentration treatment able to reactivating the silenced
PMP24 , limited demethylation was observed and interestinQlly most of
demethylation was found in two narrow regions, site I and site III (Figure 1), which
can also been found demethylated at higher concentrations. Combined with the
computational analysis results of the promoter region , we didn t identify any known
transcription factor binding elements in site I. However, site III was a potential site
for AP-2 binding with 2 CpG dinucleotides at the site. Limited demethylating
sequencing results showed that the two CpG sites at AP-2 site were preferential
sites for demethylation , indicating that these two sites and their demethylation
might be critical for the gene promoter activity and expression activation.
3.4. 2 First CpG of AP-2 cis-element but not the second was essential for
DNA-protein binding
EMSA results showed direct in vitro 
evidence of protein-DNA interaction at
this site by using a 30 bp AP-2 probe including this potential AP-2 cis-element. As
shown in Figure 2 , several DNA-protein complexes were formed by incubating
labeled probe with nuclear extract from PMP24 expressing NPrEC cells (lane 2).
One complex as indicated by an arrow was sequence-specific since it could be
competed away by a 100-molar excess of unlabeled wild type AP-2 probe (lane 4).






site I site II
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expression
Figure 1. 5AZdC treatment preferentially demethylated AP-2 cis-element in
the intron 1 of PMP24.
Limited demethylating bisulfite sequencing of PMP24 promoter CpG island in PC-
3 cells treated with 5AZAdC at different concentrations. Site I and Site II were
preferentially de methylated after the cells were treated with 5AZAdC at the lowest
concentration of 0. 1 IJM to reactivate the gene expression. Computer analysis
identified the site II region in the intron 1 as an activator protein 2 (AP-2) cis-








NPrEC 5 J-gAP2 mut mut mut met
consAP2 CG1 CG2 2CGs AP2
Figure 2. First CpG of AP-2 cis-element but not the second was essential for
DNA-protein binding.
EMSA of a 30-bp labeled oligonucleotide harboring the AP- cis-element with
nuclear extract from NPrEC demonstrated a sequence-specific protein binding at
this site, indicated by the arrow. The presence of 100-fold molar excess of AP-
consensus (lane 3), wt AP-2 (lane 4) and mutCG2 (mutation at the second CpG of
AP-2 site) (lane 6) diminished shifted labeled band while same excess amount of
mutCG1 (mutation at the first CpG of AP-2 site) (lane 5), mut2CGs (mutations at
both CpGs) (lane 7) and in vitro methylated AP-2 (lane 8) showed no competition
of binding to the labeled probe. It indicated that the first CpG of AP2 site was
critical for DNA-protein binding and the binding can be interfered by the
methylation of CpG sites.
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excess of consensus AP-2 oligonucleotides (AP-2 cons) sugglested that AP-
protein was involved in this DNA-protein interaction (lane 3). We generated
oligonucleotides with mutations at either one of the two CpG sites (mutCG1
mutCG2) and at both (mut2CGs) of AP- cis-element. These oliigos were then
used to compete with the labeled probe in EMSA to determine the specificity of the
binding site. We found that mutation at the second CpG site alone was able to
compete away the DNA-protein complex with the labeled widle type probe (lane 6),
suggesting that this site was not specific for this interaction. However, when the
first CG site was mutated either in mutCG1 or in mut2CGs, the mutated oligos
were no longer able to compete with the labeled wide type probe to abolish the
shifted band (lane 5 and 7). It suggested that the first CG site was the most critical
in this DNA-protein interaction. We further investigated the effect of CpG
methylation on this DNA-protein interaction. All the three CpG sites in the wide
type probe were methylated in vitro by Sss I methylase. EMSA assay showed that
methylated oligo was no longer able to compete with the labeled wide type oligo in
the DNA-protein interaction, indicating that methylation of these three CpG sites
steric interfered with transcription factor binding (lane 8). Due to the limitation of
site specificity of existing methylase, we were unable to methylate individual CpG
site in this oligo sequence to investigate the importance of each site in the DNA-
protein interaction by EMSA.
3 First 9pG of AP-2 cis-element but not the second was critical for
PMP24 promoter activity.
We used an alternative approach to address the importance of the AP-




plasmids and plasmids with deletion of AP- cis-element for promoter activity
assay. We performed site-directed mutagenesis on pGL3I1RES!(-347/+398)
plasmid at either the first or the second CpG site in the potential AP-2 binding
region to generate two mutated plasmids: pGL3I1RES/(-347!+398)/mutCG1 and
pGL3I1RES/(-347/+398)/mutCG2. Two additional plasmids pGIL3I1RES/(-347/+161)
and pGL3/IRES/(-347/+262)were generated with or without the 3' deletion of AP-
cis-element as illustrated in Figure 3. Promoter activity of CG1 mutant decrease
dramatically as compared to the original pGL3/IRES/(-347/+398) whereas the
CG2 mutant showed comparable activity to the original. The deletion of AP- cis-
element resulted in a similar decrease of promoter activity for pGL3I1RES/(-
347/+161) plasmid (Figure 3). These results clearly demonstrated that the AP-
cis-element in intron 1 of PMP24 is a binding site for the transcription factor and
that the resulting activity depends critically on the first CpG site within the region.
Methylation of the first CpG but not the second of the AP-2 cis-element could
potentially interfere with the DNA-protein interaction leading to the decrease in
promoter activity.
3.4.4 Methylation of AP-2 cis-element alone downregulated PMP24
expression
We next use a newly developed method , methylated o igonucleotides (MOs)
treatment (Yao et aI. , 2003; Zhu et aI., 2004b), to determine if methylation of AP-
cis-element alone is responsible for PMP24 silencing. MOs are 18-25 bp
oligonucleotides with at least three methylated CpG dinucleotides. Targeting OMs
to the specific sequences in the genome can achieve site-spedfic methylation 
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Figure 3. The first CpG of AP-2 cis-element but not the second was critical
for the PMP24 promoter activity.
Plasm ids with mutations at the two CpG dinucleotides of AP- cis-element
respectively, pGL3I1RES/(-722/+398)mutCG1 and pGL3/IRES/(-
722/+398)/mutCG2, were generated from the plasmid with PMP24 promoter
activity, pGL3/IRES/(-722/+398). Plasmid pGL3/IRES/(-722/+398) was in vitro
methylated by Sss I methylase. 3' deletion generated two adlditiional plasm ids
pGL3/IRES/(-722/+262) with AP- cis-element and pGL3I1RES/(-722/+161)
without AP- cis-element. Methylation of the whole promoter CpG island
completely abolished the promoter activity. Similar effects wel" observed for
pGL3I1RES/(-722/+398)mutCG1 and pGL3/IRES/(-722/+1611) while pGL3/IRES/(-
722/+398)mutCG2 and pGL3I1RES/(-722/+262) showed comparable activity to the
original asmid . The results indicated that the CpG methylation had strong
inhibitory effect on promoter activity and that AP- cis-element was crucial for the
activity, the first CpG in particular.
. ..,
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DNA intermediate is the preferred substrate for DNA methyl transferase I (DNMT1)
for maintenance methylation. MO targeting AP- cis-element for methylation
(metAP2) and unmethylated oligonucleotides of the same sequence used as a
control (ctrIAP2) were delivered into NPrEC prostate cells, which express PMP24
and has the PMP24 promoter CpG island mostly unmethylated. Our bisulfite
sequencing analysis of the metAP2 treated cells confirmed sellective methylation
of the AP- cis-element interestingly more only at the first CpG site, in
approximately half of the DNA population , as opposed to no methylation in ctrlAP2
treated and untreated control NPrEC cells (Figure 4B). Lack off methylation at AP-
2 cis-element in some metAP2 treated cells is probably due to the transfection
effciency and low proliferation rate of NPrEC cells since the 
in cellulo methylation
requires the delivery of MO into the cell and at least two rounds of DNA replication.
Nevertheless , in concert with the methylation status of AP-2 cis-element
transcription of PMP24 showed significant downregulation to 56% (Po:O.005) in the
metAP2 treated cells and no change in crtlAP2 treated cells compared to the
untreated NPrEC cells (Figure 4A). These data strongly sugglested that
methylation of AP-2 cis-element , especially the first CpG dinucleotides was
suffcient for the downregulation of PMP24 transcription.
5 PMP24 Silencing was under different epigenetic co,ntrol
One striking finding of the study was that the PMP24 glene is silenced in
early passage LNCaP with its promoter CpG heavily methylated to the same
extent as in LNCap and PC-3. However, when we treatedllNCaP with 5AZAdC
at various final concentrations up to 51JM , the gene reactivation was not observed,








Figure 4. Methylation of the AP-2 cis-element alone downregulated the
expression of PMP24 in cellulo.
A. Real-time PCR analysis showed significant downregulation of PMP24
expression in the NPrEC cells treated with methylated oligonucleotides, metAP2,
targeting AP- cis-element specifically for in cellula methylatiion. Treatment with
unmethylated oligonucleotides , ctrlAP2 , showed no significant effect on the gene
expression of PMP24 in NPrEC cells compared to untreated! cells. B. Bisulfite
sequencing analysis showed that AP- cis-element was speciiically methylated in
about s,?% of the clones from metAP2 treated NPrEC cells. No methylation was




same treatment (Figure 5). We then analyzed expression level of Glutathione S-
transferase P1 (GSTP1) gene, whose gene silencing is well known to be
associated with methylation in LNCaP cells, for positive control purpose.
Reactivated GSTP1 in 5AZAdC treated LNCaP cells suggested that 5AZdC is
effective (Figure 5). Bisulfite genomic sequencing of the PMP24 CpG island in
cells treated with 5AZAdC showed similar level of demethylation in all cell lines
treated at the same concentration (Figure 1 and Figure 6A). Whie we subjected
these three cell lines to the treatment of TSA, a HDAC inhibitor, we found that TSA
treatment alone was able to reactivate PMP24 expression in LNCaP. The
reactivation in LNCap and PC- , if any, was not as dramatic as in LNCaP and
combination of 5AZAdC and TSA treatments showed synerglistiic effect in
LNCap but not PC-3. ChiP assay in cells treated with 5AZAdC and TSA showed
similar changes in acetylated H3 and H4 at the PMP24 promoter region (Figure
6B). It indicated that TSA had the same effect, which is to inhibit histone
deacetylation in all the cells. The results suggested that although PMP24 is
silenced in both AD LNCaP and AI LNCap and PC-3 cells" the mechanisms for
the PMP24 silencing in these cells were apparently different.
DISCUSSION
Our previous study showed that PMP24 is silenced by a mechanism
associated with its promoter CpG island hypermethylation in lNlCap and PC-
The silenced gene can be reactivated by 5AZdC treatment n these cells.
5AZAdC covalently binds to methyltransferase to lower its activity in cells
(Christman , 2002). It is speculated that decreased methyltransferase activity leads












Figure 5. Silenced PMP24 expression AD LNCaP and AI LNCap and PC-
responded differently to different reactivating agent, 5AZAdC and TSA.
RT -PCR analysis of PMP24 expression in various prostate cancer cells treated
with 5AZAdC and/or TSA. Silenced PMP24 expression in AD ILNCaP can be
reactivated by TSA treatment alone but not 5AZAdC even at high concentration of
M. GSTP1 gene, whose silencing is well known to be reactivated by 5AZdC
treatment in LNCaP cells, is included as positive control for drug effect. In contrast
to LNCaP , PMP24 silencing in AI LNCap and PC-3 can be predominantly
reactivated by 5AZdC treatment at the concentration as low as 0. M but not
TSA alone. A synergistic effect of 5AZdC and TSA was shown in AI LNCap
but not in PC-3 cells.
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Figure 6. Same drug effects of 5AZdC and TSA on DNA Ilevel in different
PCa cells.
A. Bisulfite sequencing of PMP24 promoter CpG island in LNCaP treated with
5AZAdC at various concentration showed similar extent of demethylation as in
5AZAdC treated PC-3 cells. Each line represents a clone from direct cloning of a
573-bp PCR product amplified from bisulfie treated cells. Each circle represents
one of the 43 CpG dinucleotides in this sequenced CpG island. Filed circles
indicate methylated CpG and open ones indicated unmethylated CpG. B. ChiP
assay of PMP24 promoter region in AD LNCaP and AI LNCap and PC-3 treated
with TSA showed similar effect of this HDAC inhibitor on acetylation of histone
protein H3 and H4. 5AZAdC treatment had little effect on acetylation of H3 but not
, similar in all three cell lines. PCR amplification showed here was from -273 to
150 relative to transcriptional starting site. PCR amplification of other region of
PMP24 promoter showed similar changes in H3 and H4 acetylation after the
treatment (data not shown).
Figure 6.
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DNA of lower methylation level with less MBD proteins binding usually assembles
into less condensed chromatin structure favoring transcription. A limited number of
studies on the methylation level of particular gene promoter CpG island after
5AZAdC treatment showed general demethylation without site specificity,
providing evidences for this mechanism (Daskalakis et aI. , 2002; Pietrobono et aI.
2002). However, this general demethylation may result from the high frequency
and long duration of 5AZAdC treatments and the relatively high concentrations
ranging from 1 M to 5 M used in these studies. Reactivation of gene
transcription by resuming the transcription factor binding with the removal of
methylation from critical cis-element 
by 5AZAdC likely occurs as a much earlier
event or at a much lower concentration.
In fact, we found that the level of transcriptional reactivation of PMP24 is
associated with the concentration of 5AZAdC and the level of demethylation in the
promoter CpG island after the treatment (Figure 1). In order to iidentify the critical
cis-element the lowest concentration of 5AZAdC at 0. M, which is just enough
to reactivate the gene , was used in our study before the treated cells were
subjected to genomic bisulfite sequencing. Such an approach, which we named
as limited demethylating bisulfite sequencing, allowed us to identify a specific
region in intron 1 of PMP24 promoter CpG island that was preferentially
demethylated at this lowest concentration. This region was later characterized as
a putative AP- cis-element by computer analysis and EMSA. Methylation of CpG
dinucleotide located in the AP- cis-element has been reported to decrease basal
promoter activity of human proenkephalin gene by inhibiting AP-2 binding to the
cis-element (Comb and Goodman , 1990b). For PMP24 , we found that methylation




Most interestingly, this same CpG site, but not the second, was necessary for the
PMP24 promoter activity, suggesting that interference of transcription factor
binding at this CpG by its methylation is a possible mechanism for repression of
PMP24 expression. Our current study is the first to report successful identification
of the cis-element whose methylation is crucial for the repression of gene
transcription using limited demethylating bisulfite sequencing analysis of the gene
promoter CpG island. It suggested that this strategy is useful in identifying such
critical cis-element if the condition of 5AZdC treatment such as concentration
and duration was carefully determined.
AP-2 transcription factors represent a family of sequence-specific DNA-
binding proteins essential for transcription and evolutionarily conserved among
different species (Monge and Mitchell , 1998; Shen et aI. , 1997;, Snape et aI. , 1991).
Human AP-2, first cloned in 1988 (Willam et aI. , 1988), has been extensively
studied for it can either activate or repress transcription of a wide variety of genes
involved in important biological functions such as development and differentiation
(Hilger-Eversheim et aI., 2000). Recent studies have elucidated the diverse roles
of AP-2 proteins in various humqn malignancies such as melanoma and breast
cancer (Bar-Eli , 2001; Fuchs and Allgayer, 2003). For prostate cancer, it has been
reported that expression of AP-2 and its regulated genes was related to cell
proliferation and differentiation (Lipponen et aI. , 2000; Ruiz et al. , 2004). We
hereby provided additional evidence for the involvement of the AP-2 in prostatic
carcinogenesis by demonstrating the essential role of AP-2 cis-element in the
promoter activity of PMP24 gene, which is specifically silenced 
n PCa cell lines.
The core sequence of the AP-2 cis-element has been identified as
palindromic motifs: GCC N3 GGC, GCC N4 GGC and GCC N3/4 GGG,
fI.
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representing promiscuous GC-rich elements varying considerably in binding
affinity (Mohibullah et aI. , 1999). In vitro experiments have demonstrated that
methylation of CpG dinucleotide containing cis-elements such as Sp1 and ETS
cis-elements reduced protein binding affinity and decreased the corresponding
promoter activity. Similar effects of AP- cis-element methylation have been
reported for the promoter activity of proenkephalin gene (Comb and Goodman
1990a) and manganese superoxide dismutase (MnSOD) genre (Huang et aI.
1997g) in vitro. Therefore, it is not surprising that the methylation of the AP- cis-
element in the 5' regulatory region of PMP24 decreased the gene promoter activity
in vitro. Worth mentioning is that the critical AP- cis-element is located in the first
intron of PMP24 gene. It has been established for some time that intron 1 region
also harbors regulatory elements for gene transcription (Reisman et aI. , 1988).
However, this study present the first in vitro evidence of a sing e CpG site within a
cis-element in intron 1 is essential for the basal promoter activity of the gene and
its methylation is associated transcription repression by interfering transcription
factor binding. Moreover, using MO treatment, we observed that the
downregulation of PMP24 transcription was consistent to methylation level of the
first CpG of AP- cis-element in the endogenous genome of NPrEC cells. We
hereby provided the first in cellulo evidence supporting the critical role played by
the methylation of a single CpG in intron 1 in the gene silencing.
Most recently, it was reported that hypermethylation of an intronic CpG
island but not sequences within the promoter was associated wiith the gene
silencing of methylation-controlled DNAJ (MCJ) gene (Strathdee et aI. , 2004). It
should be noted that the most so called "promoter CpG islands." refer to the ones




There might be reason for the extension of CpG island into intron 1. We believed
that our finding of critical CpG in intron 1 of PMP24 and recent study on MCJ
promoter CpG island have shed lights on the function of intronilc CpG islands.
More studies are needed to elucidate their roles in the control of gene expression.
In our previous study, we used LNCaP in vitro culturing model system to
identify new genes whose promoter CpG island methylation is dlifferent between
AD LNCaP and AI LNCap . Since AI LNCap was derived from AD LNCaP by
long term culturing in the medium with CS-FBS, we used LNCaP of similar
passage as LNCap to exclude the possible methylation differences introduced
by the long term culturing. We found that PMP24 was expressed in the LNCaP
(passage 50-60) with fair amount of methylation in the promoter CpG island. To
test the possibility that such methylation is introduced by long term culturing as
shown in some previous studies (Antequera et aI. , 1990; Jones et aI. , 1990), we
then examined the PMP24 expression and its promoter methylation in LNCaP of
early passage (passage -: 20). To our surprise , we discovered that PMP24 was
silenced in low passage LNCaP cells and its promoter CpG island showed even
heavier methylation which was compariable to the ones in LNCap and PC-
with the exception of incomplete methylation of the first CpG of AP- cis-element
in intron 1. Our data is the first evidence to show that spontaneous demethylation
could occur during the long term cell culturing and lead to the re-expression of
related genes. Our previous study showed that PMP24 is expressed in the normal
prostate basal epithelial cells , which are considered as stem-like cells in the
normal prostate epithelium. The silencing of the gene is only presented in the
prostate cancer cells and our preliminary results suggested the anti-tumor
properties of this gene. However, the re-expression of PMP24 glene in LNCaP of
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higher passage argues against its function in the prostatic tumorigenesis and
progression into androgen- independence. One possibility is tl1at the expression of
PMP24 is simply involved in the differentiation of prostate epithelial cells. To better
understand its functions in prostate cells , the regulation of PMP24 expression in
different prostate cells as well as other types of cells needs to be further studied.
Another surprising finding of PMP24 expression in LNGaP of low passage
is that the 5AZAdC treatment showed no transcriptional reactivation of PMP24.
More strikingly, TSA treatment alone reactivated this gene in LNCaP. It has been
shown that TSA alone is able to reactivate the non-methylated gene, whose
expression is repressed by condensed chromatin , through inhibition of histone
deacetylase activity (Cameron et aI. , 1999). For the genes with hypermethylated
CpG island , their silencing can be reactivated by 5AZAdC treatment but usually
showed resistance to TSA treatment alone. To our knowledge, this is the first
report of reactivation of repressed expression of a gene with hypermethylated
CpG island by the TSA treatment alone but not the exposure to 5AZAdC.
Bisulfite sequencing analysis for the 5AZdC treated ceilis and ChiP assay
for the TSA treated cells indicated that both drugs had similaJ effects on the DNA
methylation and histone acetylation in these three cell lines. lit suggested that even
though PMP24 was silenced in both AD LNCaP and AI LNCap and PC-3, the
silencing was apparently governed by different mechanisms in these cell lines. In
AD LNCaP with first CpG of AP- cis-element incompletely methylated, PMP24
was predorTinantly repressed by inaccessible binding of transcription factor and




Therefore the silencing in LNCaP can be reactivated by TSA but not 5AZdC
treatment. However, in AI LNCap and PC-3 cells , the critical cis-element(s) for
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the promoter activity, such as the first CpG dinucleotide of the AP- cis-element
within intron 1 became completely methylated. PMP24 silencing was then
predominantly controlled through the interference of critical transcription factor
binding by DNA methylation. Thus, only when the first CpG dinucleotide of the AP-
2 cis-element was demethylated by the 5AZAdC treatment as shown in Figure 1
the gene was reactivated. TSA treatment didn t reactivate the gene since it had no
effect on the DNA methylation.
Interestingly, in a recent model for the association between gene silencing
and CpG island methylation , it was proposed that the hypermethylation associated
gene silencing is rather a gradual process to reinforce silencingl than a causing
effect of initial transcriptional silencing (Turker, 2002; Clark and Melki , 2002).
Accumulating evidences suggested that an initial transient transcriptional silencing
probably throught the related cellular signaling, along with random methylation
seeding will lead to a "permanent" silencing by spread of DNA methylation in its
promoter CpG island. The silencing of PMP24 in the most off the low passage
LNCaP cells is probably stil in the early phase of this process and therefore is
transient and can be reactivated by remodeling the chromatin structure. While in
AI LNCap and PC-3 cells , the PMP24 silencing is dominant by the complete
methylation of the critical CpG site with the spread of methylation in the PMP24
promoter CpG island.
Since the LNCap was derived from LNCaP cells, it is possible that the
population of cells with methylation silenced PMP24 were selected and give rise to
LNCap cells during the long term culture in the medium with CS-FBS. But it is
also possible that the cells with transient PMP24 silencing gradually evolved to the
methylation dominant silencing simply by the long term culturflng. To test these two
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possibilties , careful study of the LNCaP cells along the long term culturing has to
be done. Moreover, since CS-FBS is depleted of not only androgens but also the
other hormones , it is possible that the expression of PMP24 and its regulation is
not related to androgen but the other hormones. Further understanding the
silencing mechanisms for PMP24 may allow us to explore if and how the change
of mechanisms for its silencing might contribute to the development of cells from
an androgen dependent to an androgen independent state.
The last but not the least, to ultimately exclude the possibility of artifacts in
the cell culture system , clinical samples need to be studied to fUirther determine if
the similar change of methylation at this site can be observed along the
progression of the disease and if the methylation of the critical CpG of AP-2 cis-
element in intron 1 of PMP24 is involved in the gene silencing in the patients of
androgen-independent stage. In the attempt to examine the cIinical relevance of
the methylation of AP- cis-element we used laser capture microdissection to
acquire 6 neoplastic foci of both Prostatic Intraepithelial Neoplasia (PIN) and high
grade cancer (grade 3 - 5) from 3 radical prostatectomies. As shown in Figure 7
genomic bisulfie sequencing analysis of the PMP24 promoter CpG island in these
samples showed that in two out of the three cases we examined, the AP- cis-
element was not methylated while most of the other CpG sites were heavily
methylated in PIN. However, in the high-grade cancer from tile same case, the
AP- cis-element became completely methylated. Although we only examined a
very limited number of clinical samples , our preliminary data provided some
promising supportive evidence that the methylation of the first GpG of the AP-
cis-element in intron 1 of PMP24 is involved in the regulation of PMP24





Figure 7. Genomic bisulfite sequencing analysis of PMP24 promoter CpG
island in microdisected samples of prostate tumor of different stages. Six
neoplastic foci of both Prostatic Intraepithelial Neoplasia (PIN) and high grade
cancer (grade 3 - 5) were acquired from 3 radical prostatectomies by laser
capture microdissection. Genomic bisulfite sequencing showed that dispite the
heavy methylation of the other CpG sites in the PMP24 promoter CpG island, the
AP- cis-element was not methylated in two out of three cases we examined. In





Prostate Cancer (PCa) is a heterogeneous disease. It is well recognized
now that the current available molecular mechanisms underlying the PCa
progression from androgen dependent to androgen independent state are not
mutually exclusive and may contribute to the PCa progression to different extent
simultaneously. This thesis emphasized that DNA hypermethylation as an
epigenetic alternation associated with gene silencing plays a significant role in the
PCa progression , in addition to genetic and cellular changes sUich as AR gene
mutation , AR gene amplification , alternations in AR signalingl pathway.
LNCaP is a well-established androgen-dependent (AD) human PCa cell line.
Long term maintenance of this cell line in Charcoal-stripped (CS) medium gives
rise to a new derivative line insensitive to androgen , LNCap
.. 
The LNCaP cell
line model is now the most frequently used model in the study of PCa progression
into androgen independence. In this study, we used the LNCaP model to study
involvement of DNA methylation associated gene silencing in the PCa progression
from androgen dependent to androgen-independent state. We successfully used
Methylation-Sensitive Restriction Fingerprinting (MSRF), a differential methylation
screening method , to identify a novel gene, peroxisomal membrane protein 24
KDa (PMP24), whose silencing is associated with its promoter CpG island
hypermethylation in androgen-independent (AI) LNCap cells as well as PC-
PCa cells. PMP24 is an integral membrane protein of peroxiisome with two
! -
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transmembrane domains. Its expression is present in 
in vitro culture of normal
prostate epithelial cells (NPrEC) and absent in some prostate cancer cell lines
such as AI LNCap and PC-3 cells. The silencing of PMP2:4 appears to be
specific to PCa cells since it has not been found in other cancer cell lines we
tested. Although the biological function of PMP24 is stililarg:el!y unknown
inhibitory effect of PMP24 on the cell growth and colony formation suggests
antitumor properties of this gene product.
We further characterized the GC-rich sequence of PMP24 gene isolated by
MSRF. We therefore found that PMP24 gene has a CpG island encompassing
part of promoter, exon 1 and part of intron 1. Hypermethylation of PMP24
promoter CpG island appears in concert with the gene silenciing in both AI
LNCap and PC-3 cells. Demethylating agent , 5-aza- deo ycytidine (5AZAdC)
treatment reactivates the gene expression with the preferential demethylation of
an activator protein 2 (AP-2) cis-element within intron 1 of the PMP24 promoter
CpG island. The AP- cis-element contains two CpG dinucleotides. Interestingly,
our data suggested that only the first CpG appears to be critical for the
transcription factor binding and the promoter activity of PMP24 gene.
Downregulation of PMP24 expression by in cellula 
methylaUon of AP- cis-
element alone is in agreement with the silencing mechanism of PMP24 in AI
LNCap and PC-3 cells through the complete methylation of the intronic AP-
cis-element which interferes with the transcription factor binding.
We later discovered that PMP24 is silenced in the low passage AD LNCaP
cells as well, and that its promoter CpG island shows same extent of
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hypermethylation with the exception of incomplete methylation of AP- cis-element.
Strikingly, the silencing of PMP24 can not be reactivated by 5AZAdC treatment. In
contrast , reactivation of MP24 in AD LNCaP cells can be achieved by Trichostatin
A (TSA), a histone deacetylase (HDAC) inhibitor treatment alone. According to the
recently proposed model for methylation-associated silencing, some genes are
transiently silenced by cellular response to environmental signal. The transient
transcriptional silencing, together with random methylation seeding in the normally
unmethylated CpG island, lead to the methylation spreading. When the complete
methylation reaches certain critical CpG containing cis-element, the transcriptional
silencing becomes "permanent" and responses to no cellular signals. The
silencing of PMP24 in the low passage LNCaP cells may be in the early phase of
this gradual process and be transient. As the cells are evolved or selected during
the long term culture in the medium with CS-FBS, the silencing mechanism of
PMP24 became dominated by the complete methylation of the CpG in the critical
AP- cis-element in intron 1 by interference with the transcription factor binding.
Since methylation silencing of the gene could be independent of androgen , it
might contribute to the overall androgen- independence of the cells. However, In
the LNCaP model we used in this study, the CS-FBS is depleted of not only
androgen but also the other hormones. Therefore , the involvement of androgens
in the gene regulation of PMP24 or in the progression into a methylation dominant
silencing need to be further determined.
In summary, our study first identified PMP24 as a gene specifically silenced
in PCa cells. The silencing of PMP24 in AI LNCap and PC-3 cells was
associated with the hypermethylation of its promoter CpG island. We further
CHAPTER IV
identified a CpG in an AP-2 cis-element in the intron 1 of PMP2:4, whose
methylation was critical for gene silencing by interfere with the transcription factor
binding. Although PMP24 was also silenced in the low passage AD LNCaP cells,
the incomplete methylation at the CpG of AP- cis-element and! different response
to the 5AZdC and TSA treatment suggested that there was probably an
alternative mechanism involved in the PMP24 silencing at this stage. It has to be
further determined if androgens but not the other hormones are involved in the
change of the silencing mechanism. And it also needs to be carefully studied that
if the cells with methylation silenced PMP24 were selected or the cells were
evolved to a methylation dominant silencing stage during the LNCaP cells
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